

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 January 2005 (06.01.2005)

PCT

(10) International Publication Number
WO 2005/001062 A2

- (51) International Patent Classification⁷: **C12N**
- (21) International Application Number:
PCT/US2004/020454
- (22) International Filing Date: 25 June 2004 (25.06.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/482,603 25 June 2003 (25.06.2003) US
- (71) Applicant (for all designated States except US): **GENCIA CORPORATION** [US/US]; 1326 Pounding Creek Road, Charlottesville, VA 30318 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **KHAN, Shaharyar** [US/US]; 4685 South Fork Drive, North Garden, VA 22959 (US).


(74) Agent: **VORNDRAN, Charles; Thomas, Kayden, Horstmeier & Risley, LLP**, 100 Galleria Parkway, Suite 1750, Atlanta, GA 30339 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.



(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

[Continued on next page]

(54) Title: **MODIFIED VECTORS FOR ORGANELLE TRANSFECTION**



(57) Abstract: The present disclosure provides compositions and methods for direct transfection of organelle DNA in living cells. More particularly, the present disclosure is based on the use of viral vectors that contain localization signals specific for the target organelle. In one embodiment, a viral vector that has been modified to express on its surface a protein transduction domain and an organelle localization signal is provided. A viral vector comprising a desired recombinant DNA construct is introduced into cell culture or injected into an organism, wherein the viral vector transduces across the cellular membrane through its protein transduction domain and localizes to the cellular organelle by way of the organelle localization/targeting signal introducing the recombinant DNA into the interior of the organelle



BEST AVAILABLE COPY



FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/20454

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/00, 15/09, 15/63, 15/70, 15/74; C07H 21/02, 21/04
US CL : 536/23.1; 435/320.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1; 435/320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P --- A, P	WO 03/076561 (EDENHOFER et al.) 18 September 2003 (18.09.2003)	1-4 ----- 5-113
X, P --- A, P	US 2003/0186233 (CHESNUT et al.) 02 October 2003 (02.10.2003).	1-4 ----- 5-113

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

10 December 2004 (10.12.2004)

Date of mailing of the international search report

10 JAN 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Konstantina Katcheva

Telephone No. (703) 305-3388

MODIFIED VECTORS FOR ORGANELLE TRANSFECTION

CROSS REFERENCE TO RELATED APPLICATION

This application claims benefit of and priority to US Provisional Patent Application No. 60/482,603 filed on June 25, 2003, which is incorporated by
5 reference herein in its entirety.

INCORPORATION-BY-REFERENCE

This application incorporates by reference the sequence listing on the accompanying compact disc in its entirety. The filename for the sequence listing is 120701-8010.ST25.txt which was created on June 23, 2004, and is about 772 KB.

BACKGROUND

1. Field of the Disclosure

The present disclosure is generally directed to compositions and methods for transfecting cells and organelles, in particular modified viral vectors for transfecting mitochondria and chloroplasts.

2. Related Art

Mitochondria are the sole energy-producing organelles in all eukaryotic cells, and therefore play a critical role in maintaining proper cellular bioenergetics, homeostatic levels and cellular life cycles. Similarly, chloroplasts are also efficient ATP-producing machines that use light as the source of energy rather than sugars or fatty acids. Both mitochondria and chloroplasts contain
20 multiple copies of organelle DNA that is replicated and transcribed in the organelles. In mammals, mitochondrial DNA (mtDNA) is a circular, approximately 16.5 kilobase, intronless genome that encodes 13 electron transport chain (ETC) proteins, 2 ribosomal RNA's and 22 tRNA's. Chloroplast genomes range in size
25 from 40-150 kilobases. Most insights into mitochondrial genetics have come in yeast, where biolistic transformation allows for engineering of mitochondrial replicons. However, many features of mammalian mitochondrial gene expression and respiratory chain biogenesis are not reproducible in yeast.

In mammals, cytoplasmic fusion and microinjection are used to
30 introduce donor mitochondria, but these techniques fail to provide a mechanism for the direct manipulation of mtDNA. In addition the uptake of exogenous DNA into mitochondria involving the protein import pathway has been reported from two laboratories. Vestweber and Schatz (1989) Nature (London) 338:170-172

achieved uptake of a 24-bp both single- and double-stranded oligonucleotide into yeast mitochondria by coupling the 5' end of the oligonucleotide to a precursor protein consisting of the yeast cytochrome c oxidase subunit IV presequence fused to a modified mouse dihydrofolate reductase. More recently, Seibel et al. (1995) Nucleic Acids Research 23:10-17 reported the import into the mitochondrial matrix of double-stranded DNA molecules conjugated to the amino-terminal leader peptide of the rat ornithine-transcarbamylase. Both studies, however, were done with isolated mitochondria, not addressing the question of how oligonucleotide-peptide conjugates will pass the cytosolic membrane and reach mitochondrial proximity.

US Patent No. 6,171,863 discloses the use of dequalinium-DNA complexes as a vehicle for delivering DNA to the interior of cells and potentially to the mitochondria. Because the DNA is associated with dequalinium, the resulting complex has a positive charge. The positively charged complex is attracted to negatively charged compartments. Thus, US Pat. No. 6,171,863 discloses delivery of DNA to negatively charged compartments, and does not disclose the specific delivery DNA to mitochondria or chloroplasts. Indeed, no technique has been disclosed for targeting specific organelles, for example the chloroplast or mitochondria, for the delivery of nucleic acids using a receptor-independent mechanism.

Thus, the inability to specifically manipulate the chloroplast and mitochondrial genome has hampered researchers' efforts to fully understand chloroplast and mtDNA replication, transcription, and translation processes. The ability to specifically manipulate mtDNA and introduce it into living cells would greatly enhance researchers' ability to fully investigate the function of individual chloroplast/mitochondrial genes and overall chloroplast/mitochondrial function.

Furthermore, the ability to manipulate the mitochondrial genome also provides a novel method of treating diseases associated with defective mitochondrial function. With age, the function of mitochondria decreases with a marked increase of mutations and large deletions of mtDNA. In particular, oxidative damage increases with age, often leading to a higher rate of mtDNA mutations. Aside from known mtDNA mutations, several forms of cancer and neurodegeneration are associated with mutations in mtDNA. For example, mutations in mitochondrial DNA are the suspected cause of a host of

degenerative neurological diseases including Alzheimers, Parkinsons and adult-onset diabetes. These mutations result in decreased electron transport chain efficiency, and the build-up of mtDNA deletions due to free radical damage (aging).

5 In addition, given the bioenergetic functions of chloroplasts, the ability to introduce exogenous genes or otherwise manipulate the chloroplast genome could have a tremendous impact on increasing the vitality and yields of crops and other plants. For example, introduction of genes into chloroplast may lead to plants with increased viability in otherwise hostile environments and
10 increased efficiency of photosynthesis. In addition, the expression of exogenous genes within the chloroplasts is believed to be significantly more efficient in chloroplasts relative the expression of exogenous genes introduced into the nucleus of the cell. Thus transfection of chloroplasts may allow for more effective biosynthesis strategies for commercial compounds.

15 In light of the numerous disease conditions related to organelle dysfunction, there is a need for methods and compositions for treating such disease conditions. Accordingly, there is also a need for improved methods and compositions for introducing polynucleotides into specific organelles.

20 There is also a need for methods of treating diseases related to organelle dysfunction including targeting polynucleotides to dysfunctional organelles or cells.

SUMMARY OF THE DISCLOSURE

The present disclosure is generally directed to compositions, methods and systems for introducing polynucleotides into an cell or organelle of a cell, for example a eukaryotic cell. One aspect of the present disclosure provides

5 nucleic acid constructs and methods for delivering nucleic acids to specific organelles. The targeting of polynucleotides to specific organelles can be accomplished without using receptor mediated localization techniques. Receptor mediated localization techniques means techniques in which the polynucleotide construct displays a ligand or receptor that is recognized by its complement on a

10 specific organelle. A particular aspect of the disclosure provides methods and compositions for transfecting organelles by incorporating a protein transduction domain (PTD) in combination with an organelle localization/targeting signal on a vector, for example a viral vector. In one aspect of the disclosure, targeting signals do not act through a receptor:ligand interaction. Typically, the modified

15 virus expresses both a protein transduction domain as well as an organelle localization/targeting signal that can associate with a specific organelle. Suitable viral vectors include but are not limited to a viral vector such as bacteriophage lambda. Exemplary PTDs include but are not limited to HIV TAT YGRKKRRQRRR (SEQ. ID NO. 3) or RKKRRQRRR (SEQ. ID NO. 4); 11 Arginine

20 residues, or positively charged polypeptides or polynucleotides having 8-15 residues, preferably 9-11 residues. Exemplary organelle localization signals include but are not limited to those listed in Tables 1 and 2.

Another aspect of the disclosure provides a system including an intact viable cell or organism that contains a recombinant vector. The

25 recombinant vector can specifically cross the plasma membrane of the organism or cell and can localize/target to a specific organelle. The cell or organism can further contain a genome modified by the recombinant vector.

Other aspects of the disclosure provide methods of correcting polynucleotide defects, including heritable polynucleotide defects or acquired

30 polynucleotide defects, augmenting expression of specific nucleic acids, interfering with the expression of specific nucleic acids, restoring or augmenting organelle function, increasing biosynthesis of specific nucleic acids and their corresponding proteins using targeted delivery of nucleic acids to specific cellular organelles or compartments.

Still other aspects of the present disclosure are directed to minimizing or reducing disease progression, alleviating symptoms, and adjusting cellular metabolism by transfecting specific organelles. Particular aspects are directed targeted delivery of nucleic acids to organelles containing the
5 components for replication, transcription, or translation, or a combination thereof such as the mitochondrion or chloroplast.

Another aspect of the disclosure provides compositions and methods for producing cell lines with depleted mitochondrial DNA.

BRIEF DESCRIPTION OF THE DRAWINGS

10 **Figure 1A** is a diagram of a modified bacteriophage lambda expressing a fusion protein of Head protein gpD including a Protein Transduction Domain, an organelle targeting signal, and a reporter protein (Red Fluorescent Protein).

Figure 1B is a diagram of the 1185 nucleotide construct PTD-MLR-gpD encoding a Protein Transduction Domain, Mitochondrial Targeting Signal, Red
15 Fluorescent Protein fusion with gene product D.

Figure 1C is a diagram of plasmid pEXP-TMRD.

Figure 2A is a diagram of a full-length mtDNA PCR amplicon generated with sense and anti-sense primers containing internal BglII and NotI sites, respectively.

20 **Figure 2B** is a diagram of a full length mtDNA amplicon ligated to Green Fluorescent Protein (GFP) DNA.

Figure 3 is a diagram of full length mtDNA/GFP ligated to SuperCos-1.

Figure 4 is a panel of confocal fluorescence micrographs showing Mitochondrial Targeting Signal with Red Fluorescent Protein and Protein
25 Transduction Domain Containing Bacteriophage Lambda colocalizing with mitochondria in Sy5y cells in culture over a 40 minute time period. The 40-minute micrograph includes mitochondria specific dye, Mitotracker Green (Molecular Probes) to verify mitochondrial localization.

Figures 5A and 5B are Western Blots mitochondrial fractions of
30 transfected cells generated at specific time points using antibodies to Red Fluorescent Protein (RFP).

Figure 6A is a gel showing GFP message detected in mitochondrial fractions.

Figure 6B is a collection of panels (a)-(d). Panels (a)-(c) are confocal fluorescence micrographs of rho⁰ cells (a) 24 hours after transfection with RFP recombinant phage; (b) initially transfected with pMLS-LambdaR (no RFP) following second transfection with SuperCos-1/mtDNA/GFP cosmid; and (c) companion images of MitoTracker Red staining (c) to reveal location of mitochondria. Panel (d) is a scatterplot comparing fluorescence intensities among MitoTracker Red mitochondrial clusters and GFP reporter gene expression.

Figure 7 is a histogram showing dsRNA knockdown of PolG.

DETAILED DESCRIPTION OF THE DISCLOSURE

1. Definitions

In describing and claiming the disclosure, the following terminology will be used in accordance with the definitions set forth below.

As used herein, the term "purified" and like terms relate to the isolation of a molecule or compound in a form that is substantially free (at least 60% free, preferably 75% free, and most preferably 90% free) from other components normally associated with the molecule or compound in a native environment.

As used herein, the term "pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.

As used herein, the term "treating" includes alleviating the symptoms associated with a specific disorder or condition and/or preventing or eliminating said symptoms.

"Operably linked" refers to a juxtaposition wherein the components are configured so as to perform their usual function. For example, control sequences or promoters operably linked to a coding sequence are capable of effecting the expression of the coding sequence, and an organelle localization sequence operably linked to protein will direct the linked protein to be localized at the specific organelle.

"Organelle Localization Signal" or "Organelle Targeting Signal" are used interchangeably and refer to a signal that directs a molecule to a specific organelle. The signal can be polynucleotide or polypeptide signal, or can be an organic or inorganic compound sufficient to direct an attached molecule to a

desired organelle. Exemplary organelle localization signals are provided in Tables 1 and 2 and described in Emanuelson et al., Predicting Subcellular Localization of Proteins Based on Their N-terminal Amino Acid Sequence. *Journal of Molecular Biology*. 300(4):1005-16, 2000 Jul 21, and in Cline and Henry, Import and Routing of Nucleus-encoded Chloroplast Proteins. *Annual Review of Cell & Developmental Biology*. 12:1-26, 1996, the disclosures of which are incorporated herein by reference in their entirety. It will be appreciated that the entire sequence listed in Tables 1 and 2 need not be included, and modifications including truncations of these sequences are within the scope of the disclosure provided the sequences operated to direct a linked molecule to a specific organelle. Organelle localization signals of the present disclosure can have 80 to 100% homology to the sequences in Tables 1 and 2. Suitable organelle localization signals include those that do not interact with the targeted organelle in a receptor:ligand mechanism. For example, organelle localization signals include signals having or conferring a net charge, for example a positive charge. Positively charged signals can be used to target negatively charged organelles such as the mitochondria. Negatively charged signals can be used to target positively charged organelles.

"Protein Transduction Domain" or PTD refers to a polypeptide, polynucleotide, or organic or inorganic compounds that facilitates traversing a lipid bilayer, micelle, cell membrane, organelle membrane, or vesicle membrane. A PTD attached to another molecule facilitates the molecule traversing membranes, for example going from extracellular space to intracellular space, or cytosol to within an organelle. Exemplary PTDs include but are not limited to HIV TAT YGRKKRRQRRR (SEQ. ID NO. 3) or RKKRRQRRR (SEQ. ID NO. 4); 11 Arginine residues, or positively charged polypeptides or polynucleotides having 8-15 residues, preferably 9-11 residues.

As used herein, the term "exogenous DNA" or "exogenous nucleic acid sequence" refers to a nucleic acid sequence that was introduced into a cell or organelle from an external source. Typically the introduced exogenous sequence is a recombinant sequence.

As used herein, the term "transfection" refers to the introduction of a nucleic acid sequence into the interior of a membrane enclosed space of a living cell, including introduction of the nucleic acid sequence into the cytosol of a cell as well as the interior space of a mitochondria, nucleus or chloroplast. The nucleic

acid may be in the form of naked DNA or RNA, associated with various proteins or the nucleic acid may be incorporated into a vector.

As used herein, the term "vector" is used in reference to a vehicle used to introduce a nucleic acid sequence into a cell. A viral vector is virus that
5 has been modified to allow recombinant DNA sequences to be introduced into host cells or cell organelles.

As used herein, the term "organelle" refers to cellular membrane bound structures such as the chloroplast, mitochondrion, and nucleus. The term "organelle" includes natural and synthetic organelles.

10 As used herein, the term "non-nuclear organelle" refers to any cellular membrane bound structure present in a cell, except the nucleus.

As used herein, the term "polynucleotide" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as used herein
15 refers to, among others, single-and double-stranded DNA, DNA that is a mixture of single-and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. The term "nucleic
20 acid" or "nucleic acid sequence" also encompasses a polynucleotide as defined above.

In addition, polynucleotide as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions
25 may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide.

As used herein, the term polynucleotide includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs
30 with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein.

It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term polynucleotide as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, inter alia.

Oligonucleotides refers to relatively short polynucleotides. Often the term refers to single-stranded deoxyribonucleotides, but it can refer as well to single-or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs, among others.

As used herein the term "vector" means a polynucleotide molecule originating from a virus, a plasmid, or the cell of a higher organism into which another polynucleotide fragment of appropriate size can be integrated without loss of the vectors capacity for self-replication. Vectors introduce foreign or exogenous DNA into host cells, where it can be reproduced in large quantities. Examples are plasmids, cosmids, lambda phage vectors, P1 bacteriophage vectors, yeast artificial chromosomes, and mammalian artificial chromosomes. Vectors are often recombinant molecules containing nucleotide sequences sequences from several sources.

2. Transfection Compositions

The provided compositions include a polynucleotide vector operably linked to a protein transduction domain and a targeting signal. One embodiment provides a vector having a polynucleotide encoding a protein transduction domain operably linked to a targeting signal, wherein the protein transduction domain operably linked to the targeting signal is displayed on an exterior surface of the vector. The disclosed compositions and methods are useful for the transfection of eukaryotic cells and organelles, in particular mammalian cells and organelles. Cellular organelles have significant roles in the life cycle of cells and their hosts. For example, mitochondria and chloroplasts are the "powerhouses" of animal and plant cells. Because of their critical activity in maintaining cell life and bioenergetics, they play major roles in cell function and cell death. They possess their own unique genomes—which, until now, have remained unsuited to manipulation. Accordingly, some embodiments of the present disclosure provide compositions and methods for the delivery of a polynucleotide to a specific

organelle, for example to mitochondria and chloroplasts. Delivered polynucleotides can encode a functional polypeptide that can be expressed in the organelle. Expression of the polypeptide in the organelle can modulate the function of the organelle and thereby alleviate symptoms of disease related to organelle dysfunction. In one embodiment, the mitochondrial genome (SEQ. ID. NO. 6) can be transfected into an organelle, either in whole or part. In other embodiments, the polynucleotide can encode an anti-sense polynucleotide or an enzymatic polynucleotide, including, but not limited to, a DNAzyme or ribozyme.

2.1 Organelles

Other embodiments of the present disclosure are directed to specifically delivering polynucleotides to cellular compartments or organelles. The polynucleotides can encode a polypeptide or interfere with the expression of a different polynucleotide. Eukaryotic cells contain membrane bound structures or organelles. Organelles can have single or multiple membranes and exist in both plant and animal cells. Depending on the function of the organelle, the organelle can consist of specific components such as proteins and cofactors. The polynucleotides delivered to the organelle can encode polypeptides that can enhance or contribute to the functioning of the organelle. Some organelles, such as mitochondria and chloroplasts, contain their own genome. Nucleic acids are replicated, transcribed, and translated within these organelles. Proteins are imported and metabolites are exported. Thus, there is an exchange of material across the membranes of organelles. In some embodiments, polynucleotides encoding mitochondrial polypeptides are specifically delivered to mitochondria.

Exemplary organelles include the nucleus, mitochondrion, chloroplast, lysosome, peroxisome, Golgi, endoplasmic reticulum, and nucleolus. Synthetic organelles can be formed from lipids and can contain specific proteins within the lipid membranes. Additionally, the content of synthetic organelles can be manipulated to contain components for the translation of nucleic acids.

2.1.1 Mitochondria

In other embodiments of the present disclosure, modified vectors are disclosed that specifically deliver polynucleotides to mitochondria. Mitochondria contain the molecular machinery for the conversion of energy from the breakdown of glucose into adenosine triphosphate (ATP). The energy stored in the high energy phosphate bonds of ATP is then available to power cellular functions.

Mitochondria are mostly protein, but some lipid, DNA and RNA are present. These generally spherical organelles have an outer membrane surrounding an inner membrane that folds (cristae) into a scaffolding for oxidative phosphorylation and electron transport enzymes. Most mitochondria have flat shelf-like cristae,
5 but those in steroid secreting cells may have tubular cristae. The mitochondrial matrix contains the enzymes of the citric acid cycle, fatty acid oxidation and mitochondrial nucleic acids.

Mitochondrial DNA is double stranded and circular. Mitochondrial RNA comes in the three standard varieties; ribosomal, messenger and transfer,
10 but each is specific to the mitochondria. Some protein synthesis occurs in the mitochondria on mitochondrial ribosomes that are different than cytoplasmic ribosomes. Other mitochondrial proteins are made on cytoplasmic ribosomes with a signal peptide that directs them to the mitochondria. The metabolic activity of the cell is related to the number of cristae and the number of mitochondria within a
15 cell. Cells with high metabolic activity, such as heart muscle, have many well developed mitochondria. New mitochondria are formed from preexisting mitochondria when they grow and divide.

The inner membranes of mitochondria contain a family of proteins of related sequence and structure that transport various metabolites across the
20 membrane. Their amino acid sequences have a tripartite structure, made up of three related sequences about 100 amino acids in length. The repeats of one carrier are related to those present in the others and several characteristic sequence features are conserved throughout the family.

2.1.2 Chloroplasts

In another embodiment, modified vectors disclosed herein
25 specifically deliver polynucleotides to chloroplasts. The chloroplast is a photosynthetic organelle in eukaryotes with a double surrounding membrane. The fluid inside the double-membrane is called the stroma. The chloroplast has a nucleoid region to house its circular, naked DNA. The stroma is also the site of
30 the Calvin Cycle. The Calvin Cycle is the series of enzyme-catalyzed chemical reactions that produce carbohydrates and other compounds from carbon dioxide.

Within the stroma are tiny membrane sacs called thylakoids. The sacs are stacked in groups. Each group is called a granum. There are many grana in each chloroplast. The thylakoid membranes are the site of

photosynthetic light reactions. The thylakoids have intrinsic and extrinsic proteins, some with special prosthetic groups, allowing for electrons to be moved from protein complex to protein complex. These proteins constitute an electron transport system sometimes known as the Z-scheme.

5 The prosthetic group for two critical membrane proteins (P680 and P700) is a chlorophyll a pigment molecule. These chlorophyll-binding proteins give the thylakoids an intense green color. The many thylakoids in a chloroplast give the chloroplast a green color. The many chloroplasts in a leaf mesophyll cell give that cell a green color. The many mesophyll cells in a leaf give the leaf a
10 green color. The chlorophyll molecule absorbs light energy and an electron is boosted within the electron cloud in a resonating chemical structure surrounding a magnesium ion. This excited electron is removed by the surrounding electron transport proteins in the membrane. The movement of these electrons, and accompanying protons, results ultimately in the trapping of energy in a phosphate
15 bond in ATP.

The thylakoid is thus the location for light absorption and ATP synthesis. The stroma uses the ATP to store the trapped energy in carbon-carbon bonds of carbohydrates. Some chloroplasts show developing starch grains. These represent complex polymers of carbohydrates for long-term storage.

20 Given the importance of mitochondria in human disease, cell proliferation, cell death, and aging, embodiments of the present disclosure encompass the manipulation of the mitochondrial genome to supply the means by which known mitochondrial diseases (LHON, MELAS, etc.) and putative
mitochondrial diseases (aging, Alzheimers, Parkinsons, Diabetes, Heart Disease)
25 can be treated. Given the bioenergetic functions of chloroplasts, the ability to introduce exogenous genes may lead to plants with increased viability in otherwise hostile environments and increased efficiency of photosynthesis. Furthermore, the expression of exogenous genes within the chloroplasts is believed to be significantly more efficient in chloroplasts relative the expression of
30 exogenous genes introduced into the nucleus of the cell. Thus, other embodiments are directed to the transfection of chloroplasts for more effective biosynthesis strategies for commercial compounds.

Prior to the present disclosure, no effective techniques existed to introduce exogenous nucleic acids, for example DNA, and the genes they encode

into mitochondria or chloroplasts using receptor-independent methods.

Phylogenetically, mitochondria and chloroplasts resemble early bacteria. One embodiment of the present disclosure is directed to a system that utilizes viral vectors, and more preferably, bacterial viruses to transfect cell organelles

5 including chloroplasts and mitochondria. This unique molecular approach to replace, augment, or otherwise modify the chloroplast and mitochondrial genome allows, for the first time, exploration of critical questions in chloroplast and mitochondrial genetics and the development of novel therapies for mitochondrial and chloroplast related diseases.

10 **2.2 Protein Transduction Domains**

In still other embodiments, compositions for transfecting cells and organelles can be delivered from the outside of a cell or organelle to the interior of the cell or organelle by operably linking the compositions to a protein transduction domain (PTD). These small regions of proteins are able to cross the cell
15 membrane in a receptor-independent mechanism. Although several of these PTD's have been documented, the two most commonly employed PTDs are derived from TAT (Frankel and Pabo, 1988) protein of HIV and Antennapedia transcription factor from Drosophila, whose PTD is known as Penetratin.(Derossi et al., 1994)

20 The Antennapedia homeodomain is 68 amino acid residues long and contains four alpha helices. Penetratin (SEQ. ID NO. 1) is an active domain of this protein which consists of a 16 amino acid sequence derived from the third helix of Antennapedia.(Fenton et al., 1998) TAT protein (SEQ. ID NO. 2) consists of 86 amino acids and is involved in the replication of HIV-1. The TAT PTD
25 consists of an 11 amino acid sequence domain (residues 47 to 57; YGRKKRRQRRR (SEQ. ID. NO. 3)) of the parent protein that appears to be critical for uptake (Vives et al., 1997). Additionally, the basic domain Tat(49-57) or RKKRRQRRR (SEQ. ID NO. 4) (Wender et al. 2000) has been shown to be a PTD. In the current literature TAT has been favored for fusion to proteins of
30 interest for cellular import. Several modifications to TAT, including substitutions of Glutamine to Alanine, i.e., Q→A, have demonstrated an increase in cellular uptake anywhere from 90% (Wender et al. 2000) to up to 33 fold in mammalian cells. (Ho et al. 2001) The most efficient uptake of modified proteins was revealed

by mutagenesis experiments of TAT-PTD, showing that an 11 arginine stretch was several orders of magnitude more efficient as an intercellular delivery vehicle.

2.2.1 Properties of TAT-PTD

2.2.1.1 Highly efficient uptake

5 Intracellular delivery of various therapeutic proteins involving TAT-PTD fusions have proven to be quite effective. This type of fusion protein was recently utilized in the delivery of biologically active heat shock protein 70 (HSP70) into HSF -/- cells and was compared to delivery of recombinant HSP7 for the ability to confer cytoprotection against thermal stress and hyperoxia.

10 Immunocytochemistry demonstrated accumulation of intracellular HSP70 in nearly 100% of cells treated with the TAT-PTD fusion while the cells treated with recombinant HSP70 demonstrated no intracellular accumulation of recombinant HSP70 protein. (D.S. Wheeler et al, 2003) Other antioxidant enzymes such as superoxide dismutase (SOD) and catalase (CAT) have also been fused to TAT for

15 intracellular delivery. With the introduction of Tat-SOD and Tat-CAT, HeLa cells experienced an approximately 90% increase in cell viability as compared to controls.(Jin et al, 2001)

Intraperitoneal (i.p.) injection of TAT-PTD anti-apoptotic protein fusions have also demonstrated significant uptake and efficacy in neuronal cells.

20 Intraperitoneal injection of PTD-HA-Bcl-xL into mice within 1-2 hours demonstrated the ability of fusion proteins to cross the blood brain barrier. The protein fusion was able to decrease cerebral infarction up to 40% upon initiation of cerebral ischemia. (Cao, et al. 2002) A similar study utilized a Bcl-x mutant (FNK), with increased anti-apoptotic activity, to protect SH-SY5Y neuroblastoma

25 cells in vitro when exposed to staurosporine-induced apoptosis and glutamate-induced excitotoxicity. This Tat-FNK fusion was also injected i.p. into gerbils and prevented delayed neuronal death in the hippocampus caused by transient global ischemia. (Asoh, 2002)

2.2.1.2 Kinetics of Tat-PTD fusions

30 Kinetic studies on the uptake of Tat-PTD have shown that an entire cell population can reach maximum uptake of the Tat-PTD within 30 seconds to 5 minutes of exposure. (Ho et al, 2001) Tat-PTD fusion proteins vary in uptake in a tissue specific manner and also depend on the structure and size of the protein fused. Stability of transduced fusion proteins into cultured HeLa cells

demonstrated a peak concentration at approximately two hours of incubation with a steady decrease up to seventy two hours later. (Jin et al 2001) Tat-PTD has also been attached to liposomes encapsulating HPTS to assess the ability of Tat-PTD to facilitate uptake of liposomal drugs into cells. Kintetic studies

5 demonstrated accumulation in a time dependent manner. A peak concentration was achieved at approximately 24 hours and the Tat-PTD liposome fusion achieved a four fold increase in uptake as compared to Penetratin-PTD liposome fusions. (Tseng et al 2002) Tat-PTD has also been fused to Angiotensin II type I receptor (AT₁R) to investigate Tat-PTD fusion's transduction efficacy and
10 functionality in neurons. Neuronal cultures, isolated from the hypothalamus and brainstem of 1 day old Wistar-Kyoto rats (WKY), were incubated with 300ug/ML of the recombinant protein and peak florescence was noted at 30 minutes of incubation with initial fluorescence recorded within minutes.(Vazquez et al 2002) The figure below demonstrates that uptake of Tat-ptd fusions varies based on the
15 type of fusion as well as cellular target for uptake.

2.2.1.3 Cytotoxicity

The parent protein of the Tat-PTD, TAT-HIV-1 protein (SEQ. ID NO. 2), elicits inflammatory responses in several cell types. Brain microvascular endothelial cells (BMEC) exposed to Tat demonstrate marked increased levels of
20 cellular oxidative stress, decreased levels of intracellular glutathione and activated DNA binding activity and transactivation of NF-kappaB and AP-1. (Toborek et al 2003). In noting the toxicity of the parent protein the fear that Tat-PTD may exhibit similar cytotoxicity when introduced into cell culture or animal models was legitimate. However, the literature to date indicates that the Tat-PTD can
25 transduce proteins of interest to nearly 100% of a cell population without exhibiting cytotoxic effects. To overcome the difficulty of transducing primary cultures of bone cells with proteins of interests, Tat-PTD was fused to Hemaagglutinin and calcineurin to assess transduction efficiency. Exposure to both osteoblasts and osteoclasts in primary culture led to an almost 99% tranduction of the fusion
30 protein with retention in approximately 50% of the cell for up to five days. No cytotoxicity was reported upon treatement with the Tat-PTD fusion.(Svetlana et al 2002) Tat-PTD fusions have also been efficacious in tranducing pancreatic islets. To test whether Tat-PTD fusions were functional in islets, Tat-PTD was fused to β -galactosidase and introduced into insulinoma β TC-3 cells. Nearly 100% of all

cells were transduced after a 3 hour incubation. A key requirement for any therapeutic intervention with a Tat-PTD fusion is that no untoward changes in normal cell physiology or function occur. In order to ensure proper secretion of insulin, islets were transduced with Tat-PTD-Bcl-XL. The fusion was shown to reverse hyperglycemia in diabetic nude mice with the same time frame as control islets with no concomitant toxicity, thus confirming the promising use of Tat-PTD fusion proteins as potential therapeutic interventions. (Embury, et al., 2001).

2.3 Organelle Targeting Signals: Mitochondria and Chloroplasts

In still other embodiments, targeting specific polynucleotides to organelles can be accomplished by modifying vectors to express specific organelle targeting sequences, signals, or domains. These sequences target specific organelles, but in some embodiments the interaction of the targeting sequence with the organelle does not occur through a traditional receptor:ligand interaction. The eukaryotic cell comprises a number of discrete membrane bound compartments, or organelles. The structure and function of each organelle is largely determined by its unique complement of constituent polypeptides. However, the vast majority of these polypeptides begin their synthesis in the cytoplasm. Thus organelle biogenesis and upkeep require that newly synthesized proteins can be accurately targeted to their appropriate compartment. This is often accomplished by amino-terminal signaling sequences, as well as post-translational modifications and secondary structure. For mitochondria and chloroplasts, several amino-terminal targeting sequences have been deduced and are included, in part, in Tables 1 and 2.

In one embodiment, the organelle targeting sequence can contain at least two, preferably 5-15, most preferably about 11 charged groups, causing the targeting sequence to be drawn to organelles having a net opposite charge. In another embodiment, the targeting sequence can contain a series of charged groups that cause the targeting sequence to be transported into an organelle either against or down an electromagnetic potential gradient. Suitable charged groups are groups that are charged under intracellular conditions such as amino acids with charged functional groups, amino groups, nucleic acids, and the like. Mitochondrial localization/targeting signals generally consist of a leader sequence of highly positively charged amino acids. This allows the protein to be targeted to the highly negatively charged mitochondria. Unlike receptor:ligand approaches

that rely upon stochastic Brownian motion for the ligand to approach the receptor, the mitochondrial localization signal is drawn to mitochondria because of charge.

In order to enter the mitochondria, a protein generally must interact with the mitochondrial import machinery, consisting of the Tim and Tom complexes (Translocase of the Inner/Outer Mitochondrial Membrane). With
5 regard to the mitochondrial targeting sequence, the positive charge draws the linked protein to the complexes and continues to draw the protein into the mitochondria. The Tim and Tom complexes allow the proteins to cross the membranes. Accordingly, one embodiment of the present disclosure delivers
10 compositions of the present disclosure to the inner mitochondrial space utilizing a positively charged targeting sequence and the mitochondrial import machinery.

In yet another embodiment, the compositions of the present disclosure include an organelle targeting sequence, for example a mitochondria targeting sequence, operably linked to a protein transduction domain. The
15 targeting sequence can be a positively charged sequence as discussed above, and typically does not operate through traditional receptor:ligand mechanisms. The PTD domain can be an HIV TAT sequence that assists the compositions in crossing lipid bilayers such as organelle membranes or plasma membranes.

2.4 Expression of Proteins on Viral Heads: Phage Display

20 Suitable vectors of the present disclosure include, but are not limited to, viral vectors such as bacteriophage lambda. Bacteriophage lambda has emerged as an alternative vehicle for the surface display of peptides and proteins to the commonly used filamentous phage. There are a number of unique features that make lambda an attractive display vehicle including the ability to display
25 multimeric proteins, no requirement for secretion of the displayed fusion protein and the means to vary the valency of the displayed fusion protein. Protein D (gpD) is an established fusion partner for phage display, fused at its N- or C-terminus (Sternberg and Hoess, PNAS 92, 1609 (1995); Mikawa et al., JMB 262, 21 (1996)). Protein D is a small major capsid protein (109 aa) which contributes
30 to the stabilization of the phage head where it forms trimeric protrusions on the phage head. Protein D is a very efficient fusion partner for high level cytoplasmic expression of soluble heterologous proteins (Forrer and Jaussi, Gene 224, 24 (1998)).

2.5 Modified Cells and Vectors

One embodiment provides a vector including a recombinant DNA sequence comprising an organelle localization signal operably linked to a sequence encoding a protein transduction domain. In this embodiment, the recombinant viral vector is engineered to contain a protein transduction domain
5 selected for transducing the viral vector across cellular membranes. Thus, the use of such modified vectors eliminates the need for viral vectors that require transfection methods to introduce the viral vector into the cellular interior. For example, if the viral vector is a lambda bacteriophage, then the viral capsid proteins are modified to express a PTD and an organelle targeting signal on the
10 viral surface.

In accordance with another embodiment a recombinant bacteriophage expressing a PTD and an mitochondrial targeting sequence is provided which can be used for organelle transfection, for example mitochondrial transfection, and more preferably lambda bacteriophage can be used to introduce
15 exogenous nucleic acid sequences into mammalian mitochondria. This approach allows for direct manipulation of mtDNA and introduction of the circular genome at high-copy number, relying upon the properties of bacteriophage lambda to infect the cell's mitochondria. In particular, the 50 kilobase bacteriophage lambda genome can be engineered with large (>10 kilobase) inserts and packaged to
20 form active lambda phage. In one embodiment, the only lambda sequences contained in the vector are the two cos sites (12 bp each) located at the 5' and 3' ends of a linear fragment to be packaged in a lambda particle, leaving up to about 50 kb available for a nucleic acid sequence of interest. The recombinant sequences may also include an origin of replication (usually ColE1) which allows
25 replication in bacteria, and a gene coding for a selectable marker.

Another embodiment provides a recombinant lambda particle which displays a protein transduction domain and an organelle targeting signal. The lambda particle also includes a polynucleotide to be delivered to the organelle. Organelles can be transfected by contacting cells with the lambda particle. The
30 lambda particle translocates across the cellular plasma membrane via the protein transduction domain and is targeted to the organelle via the targeting signal. The polynucleotide is then delivered to the organelle.

Because the minimal mitochondrial replicon is unknown, the complete human mitochondrial genome or partial fragment thereof can be inserted

into lambda. In one embodiment this method is used to manipulate or replace mtDNA. In another embodiment the entire human mitochondrial genome (SEQ ID NO. 6) can be replaced by introduced sequences. For example, Rho⁰ cells can be first generated to remove endogenous mtDNA, followed by mitochondrial transfection, resulting in the entire mitochondrial genome of cells being replaced. Alternatively, mitochondria can be transfected without first proceeding with the generation of Rho⁰ cells. In this case the introduced nucleic acid will be incorporated (recombined) with the existing endogenous mtDNA sequences resulting in the manipulation of the mtDNA sequences. Either method can be used to restore full functionality to damaged mitochondria.

In still another embodiment, a lambda phage vector is used wherein the structural capsid proteins of the bacteriophage have been modified to allow the bacteriophage to cross the cellular membrane using a PTD and targeted to the mitochondria using a mitochondrial targeting signal. Preferably the modified phage vector protein is one that allows for the expression of protein moieties such as PTD and an organelle targeting signal. Wild type lambda phage expresses gpD on its capsid or head. The viral capsid is composed of several proteins, including the gpD protein, and this protein can be modified to produce a bacteriophage that is capable of specifically crossing cellular membranes and targeting to organelles.

Suitable mitochondria localization sequences are known to those skilled in the art (see Table 1) and include the mitochondrial localization signal of subunit VIII of human cytochrome oxidase, the yeast cytochrome c oxidase subunit IV presequence and the amino-terminal leader peptide of the rat ornithine-transcarbamylase. In one embodiment the introduced sequences are expressed on the viral capsid head. Upon expression of the recombinant viral vector, the mitochondrial localization signal causes the viral vector to be localized to the mitochondria. Transfection of this host cell with a suitable viral vector will target the vector to the mitochondria.

Nucleic acids encoding a protein of a vector, for example a viral capsid protein for a viral vector, can be operatively linked to an organelle targeting sequence, for example amino acids used to import proteins into the mitochondria. This hybrid protein can be used to target nucleic acids to the organelle. Once inside the organelle, the nucleic acid can be integrated into the genome of the

organelle. Thus, an embodiment of the present disclosure is directed to a polypeptide comprising at least a partial viral capsid protein sequence and organelle targeting sequence, for example the targeting sequences of Table 1 or Table 2. The hybrid polypeptide can be expressed independently or can be
5 expressed as part of a viral vector.

Another embodiment provides a transfection system that comprises two components, the viral vector modified to express a PTD that delivers the nucleic acid of interest, for example RNA, DNA, or a combination thereof, to the cellular interior and a organelle targeting signal, wherein the construct comprises
10 a nucleic acid sequence that encodes an organelle localization sequence operably linked to a viral surface protein specific for the viral vector. The PTD and the organelle targeting sequence can be expressed as separate polypeptides on the surface of the viral vector or in a single polypeptide sequence, fusion protein, on the surface of the viral vector. The nucleic acid construct also optionally includes a
15 suitable promoter for expressing the fusion protein as well as any other necessary regulatory elements for expressing the fusion protein. Such regulatory elements are well known to those skilled in the art and will vary based on the fusion protein expression system. One viral vector suitable for use with the present disclosure is bacteriophage lambda. When bacteriophage lambda is used as the transfection
20 vector, the component of the transfection system comprises a nucleic acid sequence encoding the lambda capsid protein(gpD) operably linked to the organelle localization sequence and protein transduction domain.

Recombinant viral vectors that comprise modified organelle targeting sequences that are expressed on the viral surface can be prepared using
25 standard molecular biology techniques. In general, a host cell is transfected with a recombinant viral construct comprising a sequence that encodes an organelle localization signal and protein transduction domain operably linked to a sequence encoding the viral surface protein, for example a viral capsid protein. The organelle localization sequence allows a protein that is linked to the localization
30 sequence (i.e., a fusion protein) to be delivered to the target organelle. According to one embodiment of the present disclosure, the localization sequence is used to target a viral vector to an organelle of choice, for example mitochondria or chloroplast, and thus provide a point for the introduced vector that targets to the

organelle. The vector is introduced into the cytosol of the cell through its protein transduction domain and then binds to the organelle specific for the vector. The nucleic acid of interest within the vector is delivered into the target animal or plant organelle.

5 Organelle localization signals are known to those skilled in the art, and any of those signals can be used to target the viral vector to the target organelle. Localization sequences suitable for use in the present disclosure are described in Emanuelson et al., Predicting Subcellular Localization of Proteins Based on Their N-terminal Amino Acid Sequence. *Journal of Molecular Biology*.
 10 300(4):1005-16, 2000 Jul 21, and in Cline and Henry, Import and Routing of Nucleus-encoded Chloroplast Proteins. *Annual Review of Cell & Developmental Biology*. 12:1-26, 1996, the disclosures of which are incorporated herein by reference in their entirety. More particularly, a list of mitochondria localization signals for targeting linked proteins or nucleic acids to the mitochondria is listed in
 15 **TABLE 1**. A list of chloroplast localization signals for targeting linked proteins or nucleic acids to the chloroplasts is listed in **TABLE 2**. In one embodiment the mitochondria or chloroplast localization signal is operably linked to a virus surface protein. It will be appreciated that part or all of the sequences listed in Tables 1 and 2 can be used as organelle targeting sequences.

20

Table 1

Localization Signals for Targeting to the Mitochondria.
 (verified using Mitochondrial Project MITOP Database --
<http://mips.gsf.de/proj/medgen/mitop/>)

25

MITOP Designation	SEQ. ID. NO.	Gene Name	Gene Name Full
106092	7	Etfa	electron transfer flavoprotein alpha chain precursor – mouse (SEQ ID NO. 7)
106098	8	Etfb	electron transfer flavoprotein beta chain – mouse (SEQ ID NO. 8)
107450	9	Dld	dihydrolipoamide dehydrogenase precursor – human (SEQ ID NO. 9)
87979	10	Ak3	nucleoside-triphosphate--adenylate kinase 3 – mouse (SEQ ID NO. 10)
88529	11	Cs	citrate synthase, mitochondrial (SEQ ID NO. 11)
891996	12	Cps1	carbamoyl-phosphate synthetase 1 (SEQ ID NO. 12)

MITOP Designation	SEQ. ID. NO.	Gene Name	Gene Name Full
97045	13	Mod2	malic enzyme complex, mitochondrial – mouse (SEQ ID NO. 13)
97499	14	Pcca	propionyl-CoA carboxylase alpha chain precursor – mouse (SEQ ID NO. 14)
A27883	15	PCCA	propionyl-CoA carboxylase alpha chain precursor (SEQ ID NO. 15)
A28053	16	Cbr2	carbonyl reductase (NADPH) – mouse (SEQ ID NO. 16)
A29881	17	mpp-2	Mitochondrial processing peptidase beta subunit precursor (beta-mpp) (ubiquinol-cytochrome c reductase complex core protein I) (SEQ ID NO. 17)
A30605	18	ACADS	acyl-CoA dehydrogenase precursor, short-chain-specific (SEQ ID NO. 18)
A31998	19	ETFA	electron transfer flavoprotein alpha chain precursor (SEQ ID NO. 19)
A32422	20	DBT	Dihydrolipoamide S-(2-methylpropanoyl)transferase precursor (SEQ ID NO. 20)
A32800	21	HSPD1	heat shock protein 60 precursor (SEQ ID NO. 21)
A36442	22	mpp-1	Mitochondrial processing peptidase alpha chain precursor (SEQ ID NO. 22)
A37033	23	IVD	isovaleryl-CoA dehydrogenase precursor (SEQ ID NO. 23)
A37157	24	BCKD	3-methyl-2-oxobutanoate dehydrogenase (lipoamide) E1-beta chain precursor (SEQ ID NO. 24)
A38234	25	OGDH	Oxoglutarate dehydrogenase (lipoamide) precursor (SEQ ID NO. 25)
A39503	26	ME2	Malate dehydrogenase (NAD+) precursor, mitochondrial (SEQ ID NO. 26)
A40487	27	FDXR	ferredoxin–NADP+ reductase, long form, precursor (SEQ ID NO. 27)
A40559	28	ACADL	long-chain-acyl-CoA dehydrogenase (LCAD) (SEQ ID NO. 28)
A40872	29	ALDH5	aldehyde dehydrogenase (NAD+) 5 precursor, mitochondrial (SEQ ID NO. 29)
A41581	30	CYP3	peptidylprolyl isomerase 3 precursor (SEQ ID NO. 30)
A42224	31	arg-2	Carbamoyl-phosphate synthase, arginine-specific, small chain precursor (arginine-specific carbamoyl-phosphate synthetase, glutamine chain) (cps-a) (SEQ ID NO. 31)
A42845	32	BDH	D-beta-hydroxybutyrate dehydrogenase precursor (3-hydroxybutyrate dehydrogenase)

MITOP Designation	SEQ. ID. NO.	Gene Name	Gene Name Full
			(fragment) (SEQ ID NO. 32)
A45470	33	HMGC	Hydroxymethylglutaryl-CoA lyase (SEQ ID NO. 33)
A47255	34	Pcx	pyruvate carboxylase (SEQ ID NO. 34)
A53020	35	PCCB	propionyl-CoA carboxylase beta chain precursor (SEQ ID NO. 35)
A53719	36	GLUDP	glutamate dehydrogenase (NAD(P)+) 2 precursor (SEQ ID NO. 36)
A55075	37	HspE1	chaperonin-10 (SEQ ID NO. 37)
A55680	38	ACADS	short/branched chain acyl-CoA dehydrogenase precursor (SEQ ID NO. 38)
A55723	39	DCI	dodecenoyl-CoA Delta-isomerase precursor, mitochondrial (SEQ ID NO. 39)
A55724	40	Acadm	Acyl-CoA dehydrogenase, medium-chain specific precursor (MCAD) (SEQ ID NO. 40)
AA227572	41	WARS2	tryptophanyl-tRNA synthetase 2 (mitochondrial – human (SEQ ID NO. 41)
AB029948	42	SerRS	mitochondrial seryl-tRNA synthetase (cDNA FLJ20450 FIS, CLONE KAT05607) – human (SEQ ID NO. 42)
ACDL_MOUSE	43	Acadl	Acyl-CoA dehydrogenase, long-chain specific precursor (LCAD) (SEQ ID NO. 43)
AF047042	44	CS	citrate synthase, mitochondrial (SEQ ID NO. 44)
AF097441	45	FARS1	phenylalanine-tRNA synthetase (FARS1) mRNA, nuclear gene encoding mitochondrial protein – human (SEQ ID NO. 45)
ATPO_HUMAN	46	ATP5O	ATP synthase oligomycin sensitivity conferral protein precursor, mitochondrial (SEQ ID NO. 46)
AXHU	47	FDX1	adrenodoxin precursor (SEQ ID NO. 47)
CCHU	48	HCS	cytochrome c (SEQ ID NO. 48)
CCNC	49	cyc-1	Cytochrome c (SEQ ID NO. 49)
CE06620	50	-	Probable leucyl-tRNA synthetase, mitochondrial (SEQ ID NO. 50)
CE09597	51	-	Pyruvate dehydrogenase (E2) dihydrolipoamide acetyltransferase (SEQ ID NO. 51)
CH10_MOUSE	52	Hspe1	10 KD heat shock protein, mitochondrial (hsp10) (10K chaperonin) mouse (SEQ ID NO. 52)
CH60_CAEEL	53	hsp60	Chaperonin homolog hsp60 precursor (heat shock protein 60) (hsp-60) (SEQ ID NO. 53)
DEHUE2	54	ALDH2	aldehyde dehydrogenase (NAD+) 2 precursor, mitochondrial (SEQ ID NO. 54)
DEHUE	55	GLUD1	glutamate dehydrogenase (NAD(P)+) precursor (SEQ ID NO. 55)
DEHULP	56	DLD	Dihydrolipoamide dehydrogenase precursor

MITOP Designation	SEQ. ID. NO.	Gene Name	Gene Name Full
			(SEQ ID NO. 56)
DEHUPA	57	PDHA1	pyruvate dehydrogenase (lipoamide) alpha chain precursor (SEQ ID NO. 57)
DEHUPB	58	PDHB	pyruvate dehydrogenase (lipoamide) beta chain precursor (SEQ ID NO. 58)
DEHUPT	59	PDHA2	pyruvate dehydrogenase (lipoamide) alpha chain precursor, testis-specific (E1) (SEQ ID NO. 59)
DEHUXA	60	BCKDH	3-methyl-2-oxobutanoate dehydrogenase (lipoamide) alpha chain precursor (SEQ ID NO. 60)
DEMSMM	61	Mor1	malate dehydrogenase precursor, mitochondrial (SEQ ID NO. 61)
DSHUN	62	SOD2	superoxide dismutase (Mn) precursor (SEQ ID NO. 62)
ECHM_HUMAN	63	ECHS1	enoyl-CoA hydratase, mitochondrial (short chain enoyl-CoA hydratase (SCEH) (SEQ ID NO. 63)
GABT_HUMAN	64	ABAT	4-aminobutyrate aminotransferase, mitochondrial precursor (gamma-amino-N-butyrate-transaminase) (GABA transaminase) (SEQ ID NO. 64)
GCDH_HUMAN	65	GCDH	glutaryl-CoA dehydrogenase precursor (GCD) human (SEQ ID NO. 65)
GCDH_MOUSE	66	Gcdh	Glutaryl-CoA dehydrogenase precursor (GCD) – mouse (SEQ ID NO. 66)
HCD1_CAEEL	67	-	Probable 3-hydroxyacyl-CoA dehydrogenase F54C8.1 (SEQ ID NO. 67)
HCD2_CAEEL	68	-	Probable 3-hydroxyacyl-CoA dehydrogenase B0272.3 (SEQ ID NO. 68)
HHMS60	69	Hsp60	heat shock protein 60 precursor (SEQ ID NO. 69)
HMGL_MOUSE	70	Hmgcl	hydroxymethylglutaryl-CoA lyase precursor (HG-CoA lyase) (HL) (3-hydroxy-3-methylglutarate-CoA lyase) (SEQ ID NO. 70)
I48884	71	-	2-oxoglutarate dehydrogenase E1 component (fragment) (SEQ ID NO. 71)
I48966	72	Aldh2	aldehyde dehydrogenase (NAD+) 2 precursor, mitochondrial (SEQ ID NO. 72)
I49605	73	Acads	Acyl-CoA dehydrogenase, short-chain specific precursor (SCAD) (butyryl-CoA dehydrogenase) (SEQ ID NO. 73)
I52240	74	ACAD	acyl-CoA dehydrogenase precursor, medium-chain-specific (SEQ ID NO. 74)
I55465	75	PDK1	pyruvate dehydrogenase kinase isoform 1 – human (SEQ ID NO. 75)
I57023	76	Sod2	superoxide dismutase (Mn) precursor

MITOP Designation	SEQ. ID. NO.	Gene Name	Gene Name Full
			(SEQ ID NO. 76)
I70159	77	PDK2	Pyruvate dehydrogenase kinase isoform 2 – human (SEQ ID NO. 77)
I70160	78	PDK3	pyruvate dehydrogenase kinase isoform 3 – human (SEQ ID NO. 78)
JC2108	79	HADH	long-chain-fatty-acid beta-oxidation multienzyme complex alpha chain precursor, mitochondrial (SEQ ID NO. 79)
JC2109	80	HADH	long-chain-fatty-acid beta-oxidation multienzyme complex beta chain precursor, mitochondrial (SEQ ID NO. 80)
JC2460	81	PC	pyruvate carboxylase precursor (SEQ ID NO. 81)
JC4879	82	SCHAD	3-hydroxyacyl-CoA dehydrogenase, short chain-specific, precursor (SEQ ID NO. 82)
KIHUA3	83	AK3	nucleoside-triphosphate--adenylate kinase 3 (SEQ ID NO. 83)
M2GD_HUMAN	84	DMGD	Dimethylglycine dehydrogenase, mitochondrial precursor (ME2GLYDH) – human (SEQ ID NO. 84)
MDHM_HUMA	85	MDH2	malate dehydrogenase mitochondrial precursor (fragment) (SEQ ID NO. 85)
O75439	86	PMPC	mitochondrial processing peptidase beta subunit precursor (beta-MPP) (P-52) (SEQ ID NO. 86)
ODO1_MOUSE	87	Ogdh	2-oxoglutarate dehydrogenase E1 component (alpha-ketoglutarate dehydrogenase) (fragment) (SEQ ID NO. 87)
ODPA_CAEEL	88	-	Probable pyruvate dehydrogenase E1 component, alpha subunit precursor (PDHE1- α) (SEQ ID NO. 88)
OWHU	89	OTC	ornithine carbamoyltransferase precursor (SEQ ID NO. 89)
OWMS	90	Otc	ornithine carbamoyltransferase precursor (SEQ ID NO. 90)
P21549	91	AGXT	alanine—glyoxylate aminotransferase (SEQ ID NO. 91)
PUT2_HUMAN	92	ALDH4	Delta-1-pyrroline-5-carboxylate dehydrogenase precursor (P5C dehydrogenase) (SEQ ID NO. 92)
Q0140	93	VAR1	VAR1 – mitochondrial ribosomal protein (SEQ ID NO. 93)
Q10713	94	KIAA0123	mitochondrial processing peptidase alpha subunit precursor (alpha-MPP) (P-55) (HA1523)

MITOP Designation	SEQ. ID. NO.	Gene Name	Gene Name Full
			(SEQ ID NO. 94)
Q16654	95	PDK4	pyruvate dehydrogenase kinase isoform 4 – human (SEQ ID NO. 95)
ROHU	96	TST	thiosulfate sulfurtransferase (SEQ ID NO. 96)
S01174	97	Got2	aspartate transaminase precursor, mitochondrial (SEQ ID NO. 97)
S08680	98	Mut	methylmalonyl-CoA mutase alpha chain precursor (SEQ ID NO. 98)
S13025	99	nuo-40	NADH dehydrogenase (ubiquinone) 40K chain (SEQ ID NO. 99)
S13048	100	cyt	cytochrome c (SEQ ID NO. 100)
S16239	101	Glud	glutamate dehydrogenase (NAD(P)+) precursor (SEQ ID NO. 101)
S23506	102	Pdha1	pyruvate dehydrogenase (lipoamide) (SEQ ID NO. 102)
S25665	103	DLAT_h	dihydrolipoamide S-acetyltransferase heart - human (fragment) (SEQ ID NO. 103)
S26984	104	-	probable DNA-directed RNA polymerase - mitochondrion plasmid maranhar (SGC3) (SEQ ID NO. 104)
S32482	105	ETFB	electron transfer flavoprotein beta chain (SEQ ID NO. 105)
S38770	106	Dci	3,2-trans-enoyl-CoA isomerase, mitochondrial precursor (dodecenoyl-CoA delta-isomerase) (SEQ ID NO. 106)
S39807	107	Bckdhb	3-methyl-2-oxobutanoate dehydrogenase (lipoamide) beta chain (SEQ ID NO. 107)
S40622	108	MUT	methylmalonyl-CoA mutase precursor (MCM) (SEQ ID NO. 108)
S41006	109	-	hypothetical protein t05g5.6 (SEQ ID NO. 109)
S41563	110	cit-1	citrate (si)-synthase, mitochondrial (SEQ ID NO. 110)
S42366	111	PRSS15	Lon proteinase homolog (SEQ ID NO. 111)
S42370	112	-	citrate synthase homolog (SEQ ID NO. 112)
S47532	113	HSPE1	heat shock protein 10 (SEQ ID NO. 113)
S53351	114	ME2.1	malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+) precursor, mitochondrial (SEQ ID NO. 114)
S60028	115	Fdxr	ferredoxin--NADP+ reductase precursor (SEQ ID NO. 115)
S65760	116	Dbt	dihydrolipoamide transacylase precursor (SEQ ID NO. 116)
S71881	117	Bckdha	branched chain alpha-ketoacid dehydrogenase

MITOP Designation	SEQ. ID. NO.	Gene Name	Gene Name Full
			chain E1-alpha precursor (SEQ ID NO. 117)
SCOT_HUMA	118	OXCT	Succinyl-CoA:3-ketoacid-coenzyme A transferase precursor (succinyl CoA:3-oxoacid CoA-transferase) (OXCT) (SEQ ID NO. 118)
SODM_CAEEL	119	sod-2	Superoxide dismutase precursor (Mn) (SEQ ID NO. 119)
SODN_CAEEL	120	sod-3	Superoxide dismutase precursor (Mn) (SEQ ID NO. 120)
SYHUA	121	ALAS2	5-aminolevulinate synthase 2 (SEQ ID NO. 121)
SYHUAL	122	ALAS1	5-aminolevulinate synthase 1 precursor (SEQ ID NO. 122)
SYLM_HUMAN	123	KIAA0028	Probable leucyl-TrNA synthetase, mitochondria precursor (Leucine-tRNA ligase) (Leurs) (KIAA0028) (SEQ ID NO. 123)
SYMSAL	124	Alas2	5-aminolevulinate synthase mitochondrial precursor (erythroid-specific) (ALAS-E) (SEQ ID NO. 124)
SYNCLM	125	leu-5	leucine-tRNA ligase precursor, mitochondrial (SEQ ID NO. 125)
SYNCYT	126	cyt-18	tyrosine-tRNA ligase precursor, mitochondrial (SEQ ID NO. 126)
SYWM_CAEEL	127	-	Probable tryptophanyl-tRNA synthetase, mitochondrial (tryptophan-tRNA ligase) (TRPRS) (SEQ ID NO. 127)
THTR_MOUSE	128	Tst	thiosulfate sulfurtransferase (SEQ ID NO. 128)
U80034	129	MIPEP	mitochondrial intermediate peptidase (SEQ ID NO. 129)
U82328	130	PDX1	pyruvate dehydrogenase complex protein X subunit precursor (SEQ ID NO. 130)
XNHU	131	GOT2	aspartate transaminase precursor, mitochondrial (SEQ ID NO. 131)
XNHUO	132	OAT	ornithine-oxo-acid transaminase precursor (SEQ ID NO. 132)
XNHUSP	133	AGXT	serine-pyruvate aminotransferase (SPT) (alanine-glyoxylate aminotransferase) (AGT) (SEQ ID NO. 133)
XNMSO	134	Oat	ornithine-oxo-acid transaminase precursor (SEQ ID NO. 134)
XXHU	135	DLAT	dihydrolipoamide S-acetyltransferase precursor (fragment) (SEQ ID NO. 135)
YAL044c	136	GCV3	GCV3 - glycine decarboxylase, subunit H (SEQ ID NO. 136)
YBL022c	137	PIM1	PIM1 - ATP-dependent protease, mitochondria (SEQ ID NO. 137)
YBL038w	138	MRPL16	MRPL16 - ribosomal protein of the large

MITOP Designation	SEQ. ID. NO.	Gene Name	Gene Name Full
			subunit, mitochondrial (SEQ ID NO. 138)
YBL080c	139	PET112	PET112 - required to maintain rho+ mitochondrial DNA (SEQ ID NO. 139)
YBL090w	140	MRP21	MRP21 - Mitochondrial ribosomal protein (SEQ ID NO. 140)
YBR120c	141	CBP6	CBP6 - apo-cytochrome B pre-mRNA processing protein (SEQ ID NO. 141)
YBR122c	142	MRPL36	MRPL36 - ribosomal protein YmL36 precursor, mitochondrial (SEQ ID NO. 142)
YBR146w	143	MRPS9	MRPS9 - ribosomal protein S9 precursor, mitochondrial (SEQ ID NO. 143)
YBR221c	144	PDB1	PDB1 - pyruvate dehydrogenase (lipoamide) beta chain precursor
YBR227c	145	MCX1	MCX1 - ClpX homologue in mitochondria
YBR251w	146	MRPS5	MRPS5 - ribosomal protein S5, mitochondrial
YBR268w	147	MRPL37	MRPL37 - ribosomal protein YmL37, mitochondrial
YBR282w	148	MRPL27	MRPL27 - ribosomal protein YmL27 precursor, mitochondrial
YCR003w	149	MRPL32	MRPL32 - ribosomal protein YmL32, mitochondrial
YCR024c	150	-	asn-tRNA synthetase, mitochondrial
YCR028c-a	151	RIM1	RIM1 - ssDNA-binding protein, mitochondrial
YCR046c	152	IMG1	IMG1 - ribosomal protein, mitochondrial
YDL202w	153	MRPL11	MRPL11 - ribosomal protein of the large subunit, mitochondrial
YDR148c	154	KGD2	KGD2 - 2-oxoglutarate dehydrogenase comple E2 component
YDR194c	155	MSS116	MSS116 - RNA helicase of the DEAD box family, mitochondrial
YDR462w	156	MRPL28	MRPL28 - ribosomal protein of the large subun (YmL28), mitochondrial
YFL018c	157	LPD1	LPD1 - dihydrolipoamide dehydrogenase precursor
YGR244c	158	LSC2	succinate-CoA ligase beta subunit
YHR008c	159	SOD2	SOD2 - superoxide dismutase (Mn) precursor, mitochondrial
YIL070c	160	MAM33	MAM33 - mitochondrial acidic matrix protein
YJL096w	161	MRPL49	MRPL49 - ribosomal protein YmL49, mitochondrial
YJR113c	162	RSM7	RSM7 - similarity to bacterial, chloroplast and mitochondrial ribosomal protein S7
YKL040c	163	NFU1	NFU1 - iron homeostasis
YLL027w	164	ISA1	ISA1 - mitochondrial protein required for norma iron metabolism
YLR059c	165	REX2	REX2 - putative 3'-5' exonuclease
YML110c	166	COQ5	COQ5 - ubiquinone biosynthesis,

MITOP Designation	SEQ. ID. NO.	Gene Name	Gene Name Full
			methyltransferase
YMR062c	167	ECM40	ECM40 - acetylornithine acetyltransferase
YMR072w	168	ABF2	ABF2 - high mobility group protein
YOL095c	169	HMI1	HMI1 - mitochondrial DNA helicase
YOR040w	170	GLO4	GLO4 - glyoxalase II (hydroxyacylglutathione hydrolase)
YOR142w	171	LSC1	LSC1 - succinate-CoA ligase alpha subunit
YPL118w	172	MRP51	MRP51 - strong similarity to S.kluyveri hypothetical protein
YPL135w	173	ISU1	ISU1 - protein with similarity to iron-sulfur cluster nitrogen fixation proteins
YPL252c	174	YAH1	YAH1 - similarity to adrenodoxin and ferredoxin
YPL262w	175	FUM1	FUM1 - fumarate hydratase
YPR047w	176	MSF1	MSF1 - phenylalanine--tRNA ligase alpha chain, mitochondrial
YPR067w	177	ISA2	ISA2 - mitochondrial protein required for iron metabolism

Table 2**5 Localization Signals for Targeting to the Chloroplast:**

Designation	SEQ. ID NO.	Description
<u>CA782533</u>	178	Transit peptide domain of the apicoblast ribosomal protein S9
P27456	179	Pea glutathione reductase (GR) signal peptide
BAB91333	180	NH ₂ -terminus of Cr-RSH encoding a putative guanosine 3',5'-bispyrophosphate (ppGpp) synthase-degradase
CAB42546	181	14-3-3 proteins
AAC64139	182	Chloroplast signal recognition particle including cpSRP54, cpSRP43 subunits or a fragment thereof
AAC64109	183	
AAD01509	184	
PWSPG, FESP1, P00221, P05435, BAA37170, BAA37171, AAA81472	185 186 187 188 189 190 191	Chloroplast transit peptides
X52428	192	AtOEP7, in particular the transmembrane domain (TMD) and its C-terminal neighboring seven-amino acid region (see Lee YJ, Plant Cell 2001 Oct; 13(10):2175-90)

Designation	SEQ. ID NO.	Description
CA757092, CA755666	193 194	THI1 N-terminal chloroplastic transit peptide, in particular 4 to 27 residues

The identification of the specific sequences necessary for translocation of a linked protein into a chloroplast or mitochondria can be determined using predictive software known to those skilled in the art, including the tools located at

5 <http://www.mips.biochem.mpg.de/cgi-bin/proj/medgen/mitofilter>.

In another embodiment, a nucleic acid encoding a vector containing a protein transduction domain and organelle localization signal can be introduced into organelles of cells from a host, primary culture, or a cell line. For example, a viral vector operatively linked with an organelle targeting sequence can be used to

10 transfect a eukaryotic cell line such that the nucleic acid sequence is stably integrated into the organelle genome of a cell of the cell line. The cell line can be a transformed cell line that can be maintained indefinitely in cell culture, or the cell line can be a primary cell culture. Exemplary cell lines are those available from American Type Culture Collection including plant cell lines which are incorporated

15 herein by reference. The nucleic acid can be replicated and transcribed within the nucleus of a cell of the transfected cell line. The targeting sequence can be enzymatically cleaved if necessary such that the vector is free to remain in the target organelle.

Any eukaryotic cell can be transfected to produce organelles that

20 express a specific nucleic acid, for example a metabolic gene, including primary cells as well as established cell lines. Suitable types of cells include but are not limited to undifferentiated or partially differentiated cells including stem cells, totipotent cells, pluripotent cells, embryonic stem cells, inner mass cells, adult stem cells, bone marrow cells, cells from umbilical cord blood, and cells derived

25 from ectoderm, mesoderm, or endoderm. Suitable differentiated cells include somatic cells, neuronal cells, skeletal muscle, smooth muscle, pancreatic cells, liver cells, and cardiac cells. Suitable plant cells can be selected from monocots and dicots, and include corn, soybeans, legumes, grasses, and grains such as rice and wheat.

If the organelle to be targeted is a chloroplast, then the host cell can be selected from known eukaryotic photosynthetic cells. If the organelle to be transfected is the mitochondrion, than any eukaryotic cell can be used, including mammalian cells, for example human cells. The cells are transfected to either
5 transiently or stably express the exogenous nucleic acid. In one embodiment a DNA construct encoding a reporter gene is integrated into the mitochondrial genome of a cell to produce a stable transgenic cell line that comprises organelles that express the desired reporter gene.

In another embodiment, siRNA or antisense polynucleotides
10 (including siRNA or antisense polynucleotides directed to mtDNA related proteins) can be transfected into an organelle using the compositions described herein.

Another embodiment of the disclosure provides a cell having a modified organelle, wherein the modified organelle includes an exogenously introduced nucleic acid. An exogenous nucleic acid means a nucleic acid not
15 naturally associated with the organelle or located in the organelle's interior. The nucleic acid expressed in the organelle can be transcribed and/or translated within the organelle. Additionally, the nucleic acid and its resultant protein can undergo posttranslational modification within the organelle, if necessary, to facilitate its function. Delivery of modified viral vectors to specific organelles can be
20 accomplished using targeting sequences, for example the targeting sequences in Table 1.

Nucleic acids including but not limited to polynucleotides, anti-sense nucleic acids, peptide nucleic acids, natural or synthetic nucleic acids, nucleic acids with chemically modified bases, RNA, DNA, RNA-DNA hybrids, enzymatic
25 nucleic acids such as ribozymes and DNAzymes, native/endogenous genes and non-native/exogenous genes and fragments or combinations thereof, can be introduced into organelles of a host cell, in particular organelles that can transcribe and or translate nucleic acids into proteins such as mitochondria and chloroplasts. In one embodiment of the present disclosure, all or part of the
30 mitochondrial or chloroplastic genome can be introduced into an organelle. The nucleic acids can be introduced into the organelle with the vector when the vector crosses the organelle membrane via protein transduction domains.

3 **Methods**

In accordance with the present disclosure one exemplary method for transfecting a cellular organelle, for example non-nuclear organelles such as the mitochondria and chloroplasts, comprises the steps of contacting a cell with a recombinant vector, for example a viral vector, wherein the vector includes a protein transduction domain and an organelle targeting signal located on the surface of the vector. Suitable cells include cells capable of being transfected, for example eukaryotic cells. Organelle targeting signals of the present disclosure include polypeptides having a net positive charge and those listed in Tables 1 and 2. Suitable PTDs include but are not limited to HIV TAT YGRKKRRQRRR (SEQ. ID NO. 3) or RKKRRQRRR (SEQ. ID NO. 4); 11 Arginine residues, or positively charged polypeptides or polynucleotides having 8-15 residues, preferably 9-11 residues. The term non-nuclear organelle is intended to encompass all organelles other than the nucleus. It will be appreciated the viral vector express a organelle targeting signal which causes the vector to associate with the organelle, typically to an organelle having a net negative charge or a region having a negative charge. In one embodiment, the association of the targeting signal with the organelle does not occur through a receptor:ligand interaction. The association of the organelle and vector can be ionic, non-covalent, covalent, reversible or irreversible. Exemplary vector:organelle associations include but are not limited to protein-protein, protein-carbohydrate, protein-nucleic acid, nucleic acid-nucleic acid, protein-lipid, lipid-carbohydrate, antibody-antigen, or avidin-biotin. The organelle targeting signal on the surface of the vector can be a protein, peptide, antibody, antibody fragment, lipid, carbohydrate, biotin, avidin, streptavidin, chemical group, or other ligand that causes specific association between the organelle and vector, preferably an electromagnetic association as between oppositely charged moieties.

The specific interaction between the introduced vector and its target organelle can be accomplished by at least two methods. In one exemplary method a recombinant viral vector can be genetically engineered to express a targeting signal, for example as a component of a polypeptide expressed on the exterior of the vector so that the targeting signal is free to interact with the targeted the organelle. Preferably, the vector expresses a surface polypeptide that is specific to the target organelle. In another method the vector is modified to incorporate an exogenous targeting protein to which an organelle binds.

Alternatively, a vector can be modified to specifically interact with a desired organelle, for example by expressing an antibody fragment that can bind to an epitope on a specific organelle. It will be appreciated by those of skill in the art that the vector can be chemically modified to have a net positive or negative charge depending on the modification agent. For example, a vector can be coated with polylysine or other agents containing a primary amino group. Additionally, amino groups can be linked to the vector or compound containing amino groups can be linked to the vector. The linkage can be reversible or irreversible, covalent or non-covalent. Other charged groups for conferring a charge to a compound are known in the art.

In accordance with another embodiment of the disclosure a modified or mutant lambda bacteriophage is used as a recombinant viral vector. Lambda phage possesses several capsid (head) proteins. gpD (gene product D) (SEQ. ID NO. 5) is a lambda phage head protein that when in its native conformation possesses free amino and carboxy termini. As such, it is common practice to express cDNA libraries on the lambda head to investigate protein interactions, wherein the expressed cDNAs are tethered to gpD at the amino or carboxy terminus and appear on the viral head surface. In order to utilize lambda phage as an organelle delivery vehicle, the free termini of gpD are modified to contain organelle targeting signals operably linked to a protein transduction domain. Accordingly, in one embodiment a lambda bacteriophage vector is selected as a delivery vehicle wherein lambda bacteriophage specifically expresses an organelle targeting signal and protein transduction domain (PTD) present on the viral capsid. The targeting signal can be a signal sequence that specifically interacts with an organelle. The PTD can also be a signal sequence that enables the viral vector to cross cellular membranes. The PTD can be positioned in the fusion protein such that after entry into the organelle, the PTD domain is cleaved from the surface of the vector causing the vector to remain trapped in the organelle. Alternatively, cleavage sites can be engineered into the expressed polypeptide so that a desired region of the polypeptide can be cleaved within the cell, for example cleavage of the PTD once the vector is localized within the organelle. The organelle targeting signal can also be cleaved from the surface of the vector. In a preferred embodiment, the PTD sequence is followed by the organelle targeting sequence. The signal sequence can be all or part of a protein,

lipid, sugar group such as a carbohydrate or a combination thereof. In this embodiment the lambda vector is introduced into the extracellular space and contacts a cell, the vector transduces across the cellular membrane and binds to its target organelle via the expressed signal sequences, and the polynucleotide present in the vector is introduced into the organelle. It will be appreciated by those skilled in the art that the target organelle can be transfected extracellularly or intracellularly. If the target organelle is transfected extracellularly, the transfected organelle can then be introduced to a cell using techniques known in the art such as fusion, electroporation, microinjection, ballistic bombardment, or liposomes.

Another embodiment provides a method for transfecting cellular organelles, for example eukaryotic organelles, by providing a virus having a targeting signal. The targeting signal can be a polypeptide, modified or unmodified, displayed on the surface of the virus which enables the virus to specifically associate with the target organelle. Exemplary targeting signals include mitochondrial targeting signals including the targeting signals listed in TABLE 1 and other signals having a net positive charge. Contacting a cell with the recombinant vector, for example a viral vector, in a manner that introduces the vector into the cytosol of said cell as an intact functioning vector. The vector then associates with its specific target organelle and the recombinant DNA is introduced into the organelle. Introduction of the recombinant DNA into the organelle can be accomplished by transducing the vector across organelle membranes via a protein transduction domain expressed on a surface of the vector.

Introduction of a vector into the cytosol of a eukaryotic cell, in an intact functional form, can be accomplished using standard techniques known to those skilled in the art or through modification of the recombinant vector with Protein Transduction Domains. Such transfection procedures include but are not limited to microinjection, electroporation, calcium chloride premeablization, polyethylene glycol permeabilization, protoplast fusion or cationic lipid premeablization. In one embodiment a viral vector is modified to include a Protein Transduction Domain that enables the entire vector to be transduced across a lipid bilayer including a cellular membrane, organelle membrane, or

plasma membrane. Suitable PTDs include but are not limited to an 11 Arginine PTD or Tat-PTD (SEQ. ID NOs. 3 or 4).

In accordance with one embodiment a method is provided for introducing exogenous nucleic acid sequences into a mitochondrion of a mammalian cell.

- 5 Any mitochondrial transfection technique should ensure that a nucleic acid crosses three membranes (the plasma membrane and the outer and inner mitochondrial membranes), addresses the high copy of mtDNA molecules, and utilizes a minimal, circular mitochondrial replicon. In one embodiment of the present disclosure a recombinant bacteriophage is used as a delivery vehicle for
- 10 introducing nucleic acid sequences into an organelle, for example the mitochondrion, wherein the vector does not bind to a lambda phage receptor expressed on the surface of the mitochondrion. Rather, the lambda phage vector associates with the mitochondrion via a mitochondrial targeting sequence, for example a targeting sequence of Table 1.

15 3.1 Transfection of Plants

- Techniques for plant transfection are known in the art. For example, *Agrobacterium tumefaciens* and *Agrobacterium rhizogenes* both have the ability to transfer portions of their DNA into the genomes of plants and can be used to transfect plant cells. The mechanism by which they transfer DNA is the same,
- 20 however the differences in the resulting phenotypes are attributed to the presence of a Ti plasmid in *Agrobacterium tumefaciens* and the Ri plasmid in *Agrobacterium rhizogenes*. The Ti plasmid DNA induces host plants to grow tumorous masses whereas the Ri plasmid DNA leads to the abundant proliferation of roots. *Agrobacterium tumefaciens* is capable of infecting almost any plant tissue whereas
- 25 *Agrobacterium rhizogenes* can only infect roots.

- The Ti plasmid of *Agrobacterium* is a large, circular double stranded DNA molecule (T-DNA) of approximately 200 kb, which exist as an autonomous replicating unit. The plasmids are maintained within the bacteria and only a specific region (T-region) approximately 20 kb can be transferred from the
- 30 bacteria to the host. To accomplish this transfer the Ti plasmid contains a series of genes that code for its own replication, excision from the plasmid, transfer to the host cell, incorporation into the host genome and the induction of tumor formation

Agrobacterium can detect and migrate towards injured plant cells through the detection of chemical signals leaking from the wounded plant. This

detection process is referred to as chemotaxis. Agrobacterium can recognize plant compounds such as acetosyringone, sinapinic acid, coniferyl alcohol, caffeic acid and methylsyngic acid which induce the bacteria's virulence. To begin the infection process, Agrobacterium must bind itself to the host cell. This binding is
5 achieved by a group of genes located within the bacterial chromosome. The bacteria can anchor at the site of injury, by the production of cellulose fibrils. The fibrils attach to the cell surface of the plant host and facilitate the clustering of other bacteria on the cell surface. It is believed that this clustering many help the successful transfer of T-DNA. Once bound to the host, the bacterium is free to
10 begin the processing and transfer of the T-region. One embodiment of the present disclosure discloses transfecting a plant cell with Agrobacterium wherein the Agrobacterium has been modified to bind to a plant organelle, for example a chloroplast. Agrobacterium can be futher modified to encode a nucleic acid of interest for expression in the organelle. Upon binding to the organelle, the
15 Agrobacterium can deliver the target nucleic acid into the chloroplast.

To transfer the T-region of the Ti plasmid to the host cell organelle, the T-region must be processed such that it is excised from the plasmid and directed to the organelle. The T-region is excised from the Ti plasmid and directed into the host cell or organelle. Once properly packaged, the T- complex transfer is
20 mediated by several proteins and is thought to be similar to bacterial conjugation. Once inside the plant cell or organelle, the T-complex is taken through the membrane.

4. Research Tools

In one embodiment, the present disclosure is used as a tool to
25 investigate cellular consequences of mtDNA expression, the mechanisms of heteroplasmy, mtDNA replication and inheritance, as well as threshold effects. Mitochondrial mutant mice can be generated using this approach, allowing investigators to study mutations in mtDNA not found in nature. More particularly, the technology can be used to generate cells that contain mitochondria that have
30 identical genotypes or varying degrees of heteroplasmy. To prepare homoplastic cells, Rho⁰ cells (devoid of mtDNA) are first prepared using RNA interference (RNAi). For example Rho⁰ cells can be generated using RNAi to the human mitochondrial DNA polymerase. Exemplary Rho⁰ cell lines are generated with RNAi to mitochondrial proteins involved in mtDNA maintenance. These Rho⁰ cells

are maintained and propagated on pyruvate containing supportive media and then transfected with a functional mitochondria genome. After metabolic selection, by removing pyruvate from supportive media, only those cells that contain successfully transfected mitochondria will survive, thus generating a population of cells that all have identical mitochondria genomes.

Cell lines having varying degrees of heteroplasmy can then be generated in a controlled manner by fusing two or more homoplasmy cell lines to generate cybrids. Cybrids can be generated using any of the known technique for introducing organelles into a recipient cell, including but not limited to polyethylene glycol (PEG) mediated cell membrane fusion, cell membrane permeabilization, cell-cytoplasm fusion, virus mediated membrane fusion, liposome mediated fusion, microinjection or other methods known in the art.

5. Transgenic Non-Human Animals

The techniques described in the present disclosure can also be used to generate transgenic non-human animals. In particular, zygote microinjection, nuclear transfer, blastomere electrofusion and blastocyst injection of embryonic stem (ES) cell cybrids have each provided feasible strategies for creating hetero- and homoplasmic mice containing mtDNA from mitofected cell lines (i.e. cells that containing transfected mitochondria). In one embodiment an embryonic stem (ES) cell is mitofected and injected into the blastocyst of a mammalian embryo as a means of generating chimeric mice. In another embodiment, embryonic stem (ES) cell cybrids (from mitofected cells and ES cell lines, or from two separately mitofected cells) are first prepared, followed by blastocyst injection into embryos as shown in Fig. 3. The use of cells carrying specific mitofected mtDNA of interest allows the creation of transmitochondrial mice that are heteroplasmic or even homoplasmic for the mitofected DNA. In theory, this technique offers the prospect of transferring any mutant mtDNA that can be obtained from cultured mitofected cells into a whole organism model.

Using lambda for mtDNA transfection will allow investigations into questions such as the effect of varying proportions of the 5000 bp "common deletion", which accumulates with aging, polymorphisms found in diabetes and neurodegenerative diseases, and dynamics of mtDNA complementation. There are also potential therapeutic uses of this approach. Targeted introduction of the normal mitochondrial genome offers treatment for both classic mtDNA-based

diseases and diseases of aging such as neurodegenerative brain conditions and adult-onset diabetes, which have been associated with mtDNA-based mitochondrial dysfunction.

6. Kits

5 The present disclosure is also directed to a kit or pack that supplies the elements necessary to conduct transfection of eukaryotic organelles. In accordance with one embodiment a kit is provided comprising a protein construct, that encodes an organelle localizing signal and protein transduction domain operably linked to a lambda surface protein, and lambda packaging components
10 for preparing a recombinant lambda vector. The kit may also include the lambda DNA sequences (the vector "arms") for inserting a DNA sequence of interest and subsequent use in generating a recombinant lambda phage vector. In one embodiment the protein construct provided with the kit comprises a mitochondrial or chloroplast localization signal selected from those known to target to the
15 organelle, partially listed in Tables I and II, and more particularly in one embodiment the protein construct comprises a sequence encoding a 11 Arginine stretch followed by the mitochondrial localization signal of subunit VIII of human cytochrome oxidase operably linked to the bacteriophage lambda gpD head protein.

20 In accordance with one embodiment a kit is provided comprising cells that contain either a mitochondria or chloroplast organelle that expresses an exogenous nucleic acid. In a further embodiment a kit is provided that comprises packaging components for a viral vector including the recombinant PTD-organelle targeting signal surface protein and viral DNA for preparing recombinant
25 constructs. In one embodiment the kit is provided with recombinant PTD-organelle targeting signal lambda surface protein, lambda bacteriophage packaging extract, and lambda DNA. The individual components of the kits can be packaged in a variety of containers, e.g., vials, tubes, microtiter well plates, bottles, and the like. Other reagents can be included in separate containers and
30 provided with the kit; e.g., positive control samples, negative control samples, buffers, cell culture media, etc. Preferably, the kits will also include instructions for use.

7. Methods of Treatment

Organelle dysfunction can cause disease in a host, for example a human host or a plant host. In particular, problems with mitochondria or chloroplasts can result in disease. Mitochondrial diseases result from failures of the mitochondria, specialized compartments present in every cell of the body except red blood cells. Cell injury and even cell death are result from mitochondrial failure. If this process is repeated throughout the body, whole systems begin to fail, and the life of the person in whom this is happening is severely compromised. The disease can be in children, for example individuals less than 18 years of age, typically less than 12 years of age, or adults, for example individuals 18 years of age or more. Thus, embodiments of the present disclosure are directed to treating a host diagnosed with an organelle related disease, in particular a mitochondrial disease, by introducing a vector into the host cell wherein the vector specifically binds to the organelle and wherein the vector comprises a nucleic acid encoding mitochondrial protein or peptide. The present disclosure encompasses manipulating, augmenting or replacing portions of the mammalian cell mitochondrial genome to treat diseases caused by mitochondrial genetic defects or abnormalities.

Exemplary mitochondrial diseases include but are not limited to: Alpers Disease; Barth syndrome; α -oxidation defects; carnitine-acyl-carnitine deficiency; carnitine deficiency; co-enzyme Q10 deficiency; Complex I deficiency; Complex II deficiency; Complex III deficiency; Complex IV deficiency; Complex V deficiency; cytochrome c oxidase (COX) deficiency; Chronic Progressive External Ophthalmoplegia Syndrome (CPEO); CPT I Deficiency; CPT II deficiency; Glutaric Aciduria Type II; lactic acidosis; Long-Chain Acyl-CoA Dehydrogenase Deficiency (LCAD); LCHAD; mitochondrial cytopathy; mitochondrial DNA depletion; mitochondrial encephalopathy; mitochondrial myopathy; Mitochondrial Encephalomyopathy with Lactic Acidosis and Strokelike episodes (MELAS); Myoclonus Epilepsy with Ragged Red Fibers (MERRF); Maternally Inherited Leigh's Syndrome (MILS); Myogastrointestinal encephalomyopathy (MNGIE); Neuropathy, ataxia and retinitis pigmentosa (NARP); Leber's Hereditary Optic Neuropathy (LHON); Progressive external ophthalmoplegia (PEO); Pearson syndrome; Kearns-Sayre syndrome (KSS); Leigh's syndrome; intermittent dysautonomia; pyruvate carboxylase deficiency; pyruvate dehydrogenase deficiency; respiratory chain mutations and deletions; Short-Chain Acyl-CoA

Dehydrogenase Deficiency (SCAD); SCHAD; and Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD).

Some mitochondrial diseases are a result of problems in the respiratory chain in the mitochondria. The respiratory chain consists of four large protein complexes: I, II, III and IV (cytochrome c oxidase, or COX), ATP synthase, and two small molecules that ferry around electrons, coenzyme Q10 and cytochrome c. The respiratory chain is the final step in the energy-making process in the mitochondrion where most of the ATP is generated. Mitochondrial encephalomyopathies that can be caused by deficiencies in one or more of the specific respiratory chain complexes include MELAS, MERFF, Leigh's syndrome, KSS, Pearson, PEO, NARP, MILS and MNGIE.

The mitochondrial respiratory chain is made up of proteins that come from both nuclear and mtDNA. Although only 13 of roughly 100 respiratory chain proteins come from the mtDNA, these 13 proteins contribute to every part of the respiratory chain except complex II, and 24 other mitochondrial genes are required just to manufacture those 13 proteins. Thus, a defect in either a nuclear gene or one of the 37 mitochondrial genes can cause the respiratory chain to break down. It will be appreciated that the scope of the present disclosure includes transfecting mitochondria with at least one or part of one gene involved in mitochondrial function, in particular at least one or part of the 37 mitochondrial genes to restore or increase the function of the respiratory chain. Any or part of a mitochondrial genome, for example human mitochondrial genome SEQ ID NO: 6, may be introduced into a host mitochondrion using the methods described herein.

Diseases of the mitochondria appear to cause the most damage to cells of the brain, heart, liver, skeletal muscles, kidney and the endocrine and respiratory systems. Thus, transfection of mitochondria in these cells and tissues with specific nucleic acids is within the scope of the present disclosure, in particular transfection of mitochondria with nucleic acids encoding mitochondrial-encoded proteins rather than nuclear-encoded proteins. It will be appreciated that the mitochondria can be transfected to express any protein whether naturally present in the mitochondrion or not or naturally encoded by mtDNA or nuclear DNA. Depending on which cells are affected, symptoms may include loss of motor control, muscle weakness and pain, gastro-intestinal disorders and swallowing difficulties, poor growth, cardiac disease, liver disease, diabetes,

respiratory complications, seizures, visual/hearing problems, lactic acidosis, developmental delays and susceptibility to infection.

Exemplary mtDNA mutations that can be addressed by the present disclosure include but are not limited to: tRNA^{leu}- A3243G, A3251G, A3303G, T3250C T3271C and T3394C; tRNA^{Lys}- A8344G, G11778A, G8363A, T8356C; ND1- G3460A; ND4- A10750G, G14459A; ND6-T14484A; 12S rRNA-A1555G; MTTS2-C12258A; ATPase 6-T8993G, T8993C; tRNA^{Ser}(UCN)-T7511C; 11778 and 14484, LHON mutations as well as mutations or deletions in ND2, ND3, ND5, cytochrome b, cytochrome oxidase I-III, and ATPase 8.

One embodiment of the present disclosure provides a method for restoring or increasing respiratory chain function in a host cell including introducing a vector into the host cell, wherein the vector specifically binds to the mitochondrion and comprises a nucleic acid that encodes a respiratory chain protein or peptide. The nucleic acid of the vector can be injected or otherwise delivered into the interior of the mitochondria when the vector targets the mitochondria, for example when the vector is bacteriophage lambda and the viral surface protein is gpD operably linked to a protein transduction domain and mitochondrial localization signal.

Another embodiment of the present disclosure provides a method for restoring or increasing cytochrome oxidase activity in a host including transfecting mitochondria in a cell, for example a skeletal muscle cell, wherein the vector comprises a nucleic acid that encodes cytochrome oxidase or a functional component thereof. A functional component means a part or fragment of the protein or protein complex or subunit that performs a biological function independently or in combination with another protein, fragment, or subunit.

Still another embodiment of the present disclosure provides a method of increasing or restoring β -oxidation in a host including obtaining cells from the host, transfecting an organelle in the cells from the host, introducing a vector comprising a nucleic acid encoding proteins involved in β -oxidation spiral and carnitine transport, wherein the vector specifically binds to the organelle; and introducing the transfected cells of the host back into the host.

Other embodiments of the disclosure are directed to methods of restoring mitochondrial function lost or decreased as a result of point mutations or deletions. For example, KSS, PEO and Pearson, are three diseases that result

from a type of mtDNA mutation called a deletion (specific portions of the DNA are missing) or mtDNA depletion (a general shortage of mtDNA). Thus, cells from hosts diagnosed with KSS, PEO, Pearson or similar disease can have their mitochondria transfected with the recombinant viral vector. A vector comprising a nucleic acid that corresponds to the deletion in the mtDNA causing the diseased state can be introduced into the cells. The vector will bind the organelle and deliver the nucleic acid into the interior of the mitochondria where the nucleic acid is expressed. The expression product can then incorporate into the mitochondria and increase or restore mitochondrial function. The transfected cells can be reintroduced in the host. It will be appreciated that the host's cells or other cells can be transfected as described herein and introduced into a host having a dysfunctional organelles, in particular mitochondria.

It will be appreciated by those skilled in the art that the present disclosure encompasses delivering either separately or in combination nucleic acids to the mitochondria that are naturally encoded by mtDNA or nuclear DNA.

The present disclosure also contemplates alleviating the symptoms of mitochondrial diseases by creating cells having transfected and non-transfected mitochondria. Alternatively, all of the mitochondria in a cell can be transfected or replaced.

One embodiment provides a method for compensating for a mtDNA mutation in a host, the method including identifying a host having a mtDNA mutation, obtaining a cell comprising said mtDNA mutation from said host, transfecting a mitochondrion of the host cell, introducing a vector that specifically binds to the organelle into the host cell, wherein the vector comprises a nucleic acid that encodes a functional product corresponding to the mtDNA mutation, introducing said transfected cell into the host. A nucleic acid that encodes a functional product corresponding to the mtDNA mutation means a sequence that produces a protein without the corresponding mutation. For example, if a host cell has an ND4- A10750G mutation, the transfected nucleic acid would encode a wildtype product for the ND4 gene. The viral vector can be introduced into the host, for example, intravenously.

8. Depletion of Organelle-Specific Polynucleotides

Another embodiment provides a method for depleting organelle polynucleotides, for example mitochondrial or chloroplast polynucleotides. The

method includes contacting a cell with at least one inhibitory nucleic acid, for example siRNA, specific for a polymerase, for example an organelle specific polymerase. One exemplary polymerase is POLy. The inhibitory nucleic acid can be selected from sequences listed in TABLE 3 or a sequence having 80-100%
5 homology to the sequences listed in TABLE 3. The inhibitor nucleic acid can be delivered to the organelle of interest using the compositions disclosed herein or using conventional transfection techniques.

Still another embodiment provides a method of depleting mtDNA in a cell including contacting the cell with an inhibitor of mtDNA replication or
10 transcription. The inhibitor of mtDNA replication can be an antisense polynucleotide or a small inhibitory RNA, or a combination thereof. It will be appreciated that the inhibitor can be DNA, RNA or a combination thereof. Exemplary inhibitors are selected from Table 3.

In some embodiments, the inhibitor is specific for a gene involved in
15 mitochondrial DNA transcription or replication. Exemplary genes include, but are not limited to, Poly, TFAM A and B, and mtSSB. Generally, genes that encode a mitochondrial or chloroplast polymerase can be used.

Another embodiment provides a cell having an inhibitory polynucleotide that specifically binds to a polynucleotide encoding a mitochondrial
20 polymerase. The cell can contain an siRNA specific for a mitochondrial polymerase, for example Poly or a vector that expresses the inhibitory polynucleotide.

9. Administration

The compositions provided herein may be administered in a
25 physiologically acceptable carrier to a host. Preferred methods of administration include systemic or direct administration to a cell. The compositions can be administered to a cell or patient, as is generally known in the art for gene therapy applications. In gene therapy applications, the compositions are introduced into cells in order to transfect an organelle. "Gene therapy" includes both conventional
30 gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or RNA.

The modified vector compositions can be combined in admixture with a pharmaceutically acceptable carrier vehicle. Therapeutic formulations are prepared for storage by mixing the active ingredient having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronics or PEG.

The compositions of the present disclosure can be administered parenterally. As used herein, "parenteral administration" is characterized by administering a pharmaceutical composition through a physical breach of a subject's tissue. Parenteral administration includes administering by injection, through a surgical incision, or through a tissue-penetrating non-surgical wound, and the like. In particular, parenteral administration includes subcutaneous, intraperitoneal, intravenous, intraarterial, intramuscular, intrasternal injection, and kidney dialytic infusion techniques.

Parenteral formulations can include the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampules or in multi-dose containers containing a preservative. Parenteral administration formulations include suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, reconstitutable dry (i.e. powder or granular) formulations, and implantable sustained-release or biodegradable formulations. Such formulations may also include one or more additional ingredients including suspending,

stabilizing, or dispersing agents. Parenteral formulations may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution. Parenteral formulations may also include dispersing agents, wetting agents, or suspending agents described herein. Methods for preparing these

5 types of formulations are known. Sterile injectable formulations may be prepared using non-toxic parenterally-acceptable diluents or solvents, such as water, 1,3-butane diol, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic monoglycerides or diglycerides. Other parentally-administrable formulations include microcrystalline forms, liposomal preparations, and

10 biodegradable polymer systems. Compositions for sustained release or implantation may include pharmaceutically acceptable polymeric or hydrophobic materials such as emulsions, ion exchange resins, sparingly soluble polymers, and sparingly soluble salts.

Pharmaceutical compositions may be prepared, packaged, or sold in

15 a buccal formulation. Such formulations may be in the form of tablets, powders, aerosols, atomized solutions, suspensions, or lozenges made using known methods, and may contain from about 0.1% to about 20% (w/w) active ingredient with the balance of the formulation containing an orally dissolvable or degradable composition and/or one or more additional ingredients as described herein.

20 Preferably, powdered or aerosolized formulations have an average particle or droplet size ranging from about 0.1 nanometers to about 200 nanometers when dispersed.

As used herein, "additional ingredients" include one or more of the following: excipients, surface active agents, dispersing agents, inert diluents,

25 granulating agents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents, preservatives, physiologically degradable compositions (e.g., gelatin), aqueous vehicles, aqueous solvents, oily vehicles and oily solvents, suspending agents, dispersing agents, wetting agents, emulsifying agents, demulcents, buffers, salts, thickening

30 agents, fillers, emulsifying agents, antioxidants, antibiotics, antifungal agents, stabilizing agents, and pharmaceutically acceptable polymeric or hydrophobic materials. Other "additional ingredients" which may be included in the pharmaceutical compositions are known. Suitable additional ingredients are

described in Remington's Pharmaceutical Sciences, Mack Publishing Co.,
Genaro, ed., Easton, Pa. (1985).

Dosages and desired concentrations of modified vectors disclosed
herein in pharmaceutical compositions of the present disclosure may vary
5 depending on the particular use envisioned. The determination of the appropriate
dosage or route of administration is well within the skill of an ordinary physician.
Animal experiments provide reliable guidance for the determination of effective
doses for human therapy. Interspecies scaling of effective doses can be
performed following the principles laid down by Mordenti, J. and Chappell, W.
10 "The use of interspecies scaling in toxicokinetics" In Toxicokinetics and New Drug
Development, Yacobi et al., Eds., Pergamon Press, New York 1989, pp. 42-96.

EXAMPLES

Example 1

Modification of the Bacteriophage Lambda Head Protein D

gpD (gene product D) was PCR amplified using the Stratagene
5 Hotstart Herculanase PCR polymerase from Lambda genome (NEB) with the
following forward and reverse primers designed to contain BglII and NotI ends,
respectively. Of note, the stop codon in the reverse oligonucleotide was removed.
The cDNA was digested with BglII and NotI (NEB) and cloned into the BglII and
NotI sites of pThioHisA (Stratagene). The resultant vector was named pThio-gpD.
10 A start Methionine and subsequent 11 Arginine containing forward oligonucleotide
was designed for PCR amplification of the mitochondrial localized Discosoma Red
Fluorescent Protein (RFP) from pDsRed2-Mito (Clontech). The forward
oligonucleotide also carried a 5' KpnI site. The reverse oligonucleotide was
designed to remove the stop codon from the mitochondrially localized RFP and a
15 5' BglII site was introduced. PCR amplification using Hotstart Herculanase

PCR polymerase was carried out on pDsRed2-Mito using the forward and
reverse primers mentioned to generate a cDNA containing a 5' KpnI site followed
by a start Methionine codon, 11 Arginine codons, the cDNA for the mitochondrially
localized RFP ending in a 3' BglII site. The cDNA construct was digested with
20 KpnI and BglII and cloned into pThio-gpD digested with KpnI and BglII. The
resultant plasmid was named pEXP-TMRD (Expression plasmid for Transducing
Mitochondrial Red fluorescent protein gpD) (Figure 1C).

pEXP-TMRD was used to transform DH5 α cells. Colonies were
isolated and sequenced for the proper plasmid. The colony containing the correct
25 construct was grown in 10 milliliter culture to an optical density value of .5. IPTG
was added to 1mM to induce expression of the TMRD protein. The culture was
incubated for 4 hours in a 37 °C shaking incubator. The bacterial culture was
centrifuged and the resulting pellet frozen overnight at -80 C. The pellet was
resuspended in 5 ml BPER lysis reagent (Pierce). Lysozyme, 100ul of 10mg/ml
30 stock solution (Pierce), was added to the suspension to a final concentration of
200 ug/ml. The resultant mixture was incubated at room temperature for 5
minutes. 15 ml of 1:10 diluted BPER reagent were added to the suspension, and
mixed by vortexing. In order to collect the inclusion bodies containing the TMRD

protein, centrifugation at 27,000 g was done for 15 minutes. The pellet was resuspended in 20 ml of 1:10 diluted BPER Reagent. The centrifugation and pellet resuspension steps were repeated two more times. The inclusion bodies were solubilized with 7 M urea, 1 mM DTT, 50 mM Tris-HCl (pH 8.0), and 150 mM NaCl.

5 The solubilized inclusion bodies were dialyzed against saline containing 33% PBS overnight. Further purification was carried out using the HisPatch Thiofusion S.N.A.P. purification columns (Invitrogen) following manufacture's directions. The resulting protein concentrate was incubated with enterokinase at 1mg/ml overnight at room temperature. Protein concentration was quantified with the Lowry assay

10 (Biorad). Purified TMRD was introduced into the GigaPack Gold packaging extract (Stratagene) to a final concentration of .5 mg/ml. The final lambda packaging extract containing TMRD in excess was used immediately.

Example 2

15 Transfection of Mitochondria in Living Cells and Expression of a Recombinant Gene Construct

Through PCR, a full-length mitochondrial genome using established primers to amplify the entire mitochondrial genome sequence of Sy5y cells was generated. The full-length mtDNA was digested with BglII and NotI. Once

20 digested, a NotI, BglII digested GFP was ligated to mtDNA amplicon. To this larger molecule, the Cos sites were ligated to generate a packageable construct. The cloning strategy is outlined below.

A full length mtDNA PCR amplicon is generated with sense and anti-sense primers containing internal BglII and NotI sites, respectively, and digested with

25 BglII and NotI (Figure 2A). A GFP DNA will be excised from its vector, pEGFP-1, using BglII and NotI sites. This GFP construct will be ligated to the mtDNA amplicon generated by PCR and digested. The resulting molecule may contain both 5' and 3' sense GFPs (Figure 2B).

A GFP that has been mutated to be expressed only in mitochondria was

30 used. Briefly, the 60th codon of the GFP mRNA is a UGG—it is read as a tryptophan by both the nuclear and mitochondrial translation apparatus. By mutating this codon to a UGA generates a stop if translated by the nucleus, but is translated as a tryptophan in the mitochondria. This strategy takes advantage of the difference between mitochondrial and nuclear codons producing a curtailed

non-fluorescing protein if translated in the ER otherwise producing a full length GFP in the mitochondria. This GFP construct was ligated to the full length mtDNA amplicon (Figure 3).

Once the construct illustrated in Figure 3 was packaged with packaging
5 extract including the recombinant PTD-organelle targeting signal capsid protein, the active phage particles were introduced into the extracellular media of cells devoid of mtDNA generated with RNAi. Since the recombinant capsid protein contains a reporter gene, RFP, confocal microscopy was used to follow and verify the location of the recombinant viral vector (Figure 4). The 40-minute micrograph
10 includes mitochondria specific dye, Mitotracker Green (Molecular Probes) to verify mitochondrial localization.

Mitochondrial targeting was further verified with western blotting of mitochondrial fractions generated at specific time points using antibodies to RFP (Clontech) and Cytochrome C (Pharmingen) (Figure 5). A mitochondrial fraction
15 was prepared from Sy5y cells in culture at several time points after introducing the modified bacteriophage lambda viral vector and immunoblotted with an anti-RFP antibody (Clontech). The same mitochondrial fractions that contained an anti-RFP signal were probed with an anti-body for cytochrome C, an endogenous mitochondrial matrix protein. RFP immunoblot showing isolated (Control) TMRD
20 and 0, 10, 20, 25, 30, and 35 minutes after introduction of the modified lambda viral vector into the cellular media. These blots indicate that the viral vector was able to cross the cellular and mitochondrial membranes, reaching the mitochondrial inner matrix. Cytochrome C immunoblot from the 10, 20, 25, 30, and 35 minute mitochondrial fractions positive for RFP.

25 Figure 6A shows the successful introduction of lambdaphage targeted to mitochondria. Figure 6A shows GFP message in mitochondria (demonstrated with RT-PCR). This approach yields very efficient GFP expression in mitochondria, shown by the correlation graph in Figure 6d. Thus successfully demonstrated the ability of the technology to reintroduce intact mitochondrial
30 genomes into rho⁰ SY5Y cells. Figure 6B shows (a) appearance of p0 cells 24 hours after transfection with RFP recombinant phage; (b) appearance of p0 cells transfected with SuperCos-1/mtDNA/GFP recombinant phage construct under green fluorescence after 24 hours; (c) companion images of MitoTracker Red

staining (c) to reveal location of mitochondria. Panel (d) is a scatterplot comparing fluorescence intensities among MitoTracker Red mitochondrial clusters and GFP reporter gene expression.

5 Example 3

siRNA knockdown of PolG

RNA interference (RNAi) is based on an evolutionarily conserved mechanism to prevent replication and expression of exogenous double-stranded RNA. While initially described in plants, RNAi has now been described in
10 eukaryotic, vertebrate, and mammalian cells. The basic mechanism depends on the generation of small RNA duplexes of 21-23 nucleotides in length and with 2-3 nucleotide overhangs at each end. In cells infected with exogenous RNA viruses, these small interfering RNA's (siRNA's) are produced by the action of a RNAase complex known as "dicer". The siRNA's thus generated (or supplied as
15 exogenous duplexes or generated internally from vectors) then form an RNA-induced silencing complex (RISC), which utilizes the anti-sense RNA strand to hybridize to the specific mRNA gene product. RISC then can create a new RNA duplex that dicer or perhaps RISC itself can degrade.

RNA silencing of mitochondrial polymerase PolG occurs within 3 days.
20 Rho⁰ cell lines were created by chronic incubation with the mutagen ethidium bromide to provide a slow mutagenesis and depletion of mtDNA. To develop more useful cell lines, a molecular RNA interference approach to silence the PolG gene was utilized and described here for the first time. The results of this experiment are shown in Figure 7. RNA silencing of the POLG gene. (top)
25 Locations of unique sequences in POL-γ mRNA chosen for RNA duplex construction. Three different duplexes were synthesized and tested. (bottom) complete loss of GFP fluorescence over 72 hrs after lipofection of RNA duplexes, indirectly indicating silencing of POLG.

The PolG gene (SEQ ID NO.: 195) was examined and several apparently
30 unique sequences were defined to create appropriate siRNA duplexes and exemplary target sequences and siRNA sequences are provided in Table 3. Representative siRNAs were introduced by lipophilic amine into cells transfected with the recombinant lambda vector. Because mtDNA synthesis and transcription

are so closely linked, the loss of GFP signal was followed as a marker for loss of PolG activity (Figure 7).

TABLE 3
PolG siRNA Sequences

5

Target sequence 1: AAGGTGGCCGGCGCCACCGTC (SEQ ID NO. 196)
Position in gene sequence: 22 GC content: 76.2% Sense strand siRNA: GGUGGCCGGCGCCACCGUctt (SEQ ID NO. 197) Antisense strand siRNA: GACGGUGGCGCCGGCCACctt (SEQ ID NO. 198)
Target sequence 2: AACAGCAGCCTCAGCAGCCGC (SEQ ID NO. 199)
Position in gene sequence: 158 GC content: 66.7% Sense strand siRNA: CAGCAGCCUCAGCAGCCGctt (SEQ ID NO. 200) Antisense strand siRNA: GCGGCUGCUGAGGCUGCUGctt (SEQ ID NO. 201)
Target sequence 3: AAGTGCTATCCTCGGAGGGCG (SEQ ID NO. 202)
Position in gene sequence: 179 GC content: 61.9% Sense strand siRNA: GUGCUAUCCUCGGAGGGGctt (SEQ ID NO. 203) Antisense strand siRNA: CGCCCUCCGAGGAUAGCActt (SEQ ID NO. 204)
Target sequence 4: AACCCATTGGACATCCAGATG (SEQ ID NO. 205)
Position in gene sequence: 214 GC content: 47.6% Sense strand siRNA: CCCAUUGGACAUCCAGAUGctt (SEQ ID NO. 206) Antisense strand siRNA: CAUCUGGAUGUCCAAUGGGctt (SEQ ID NO. 207)
Target sequence 5: AAATCTTCGGGCAAGGAGGGG (SEQ ID NO. 208)
Position in gene sequence: 257 GC content: 57.1% Sense strand siRNA: AUCUUCGGGCAAGGAGGGGctt (SEQ ID NO. 209) Antisense strand siRNA: CCCCUCCUUGCCCGAAGAUctt (SEQ ID NO. 210)
Target sequence 6: AAGGAGGGGAGATGCCTGGCG (SEQ ID NO. 211)
Position in gene sequence: 269 GC content: 66.7% Sense strand siRNA: GGAGGGGAGAUGCCUGGCGctt (SEQ ID NO.212) Antisense strand siRNA: CGCCAGGCAUCUCCCCUCctt (SEQ ID NO. 213)
Target sequence 7: AAGCACGGGCTCTGGGGGCAG (SEQ ID NO. 214)

Position in gene sequence: 325 GC content: 71.4% Sense strand siRNA: GCACGGGCUCUGGGGGCAGtt (SEQ ID NO. 215) Antisense strand siRNA: CUGCCCCCAGAGCCCGUGCtt (SEQ ID NO. 216)
Target sequence 8: AACCTGGACCAGCACTTCCGC (SEQ ID NO. 217)
Position in gene sequence: 400 GC content: 61.9% Sense strand siRNA: CCUGGACCAGCACUUCCGctt (SEQ ID NO. 218) Antisense strand siRNA: GCGGAAGUGCUGGUCCAGGtt (SEQ ID NO. 219)
Target sequence 9: AAGCAGAGCCTGCCCTACCTG (SEQ ID NO. 220)
Position in gene sequence: 433 GC content: 61.9% Sense strand siRNA: GCAGAGCCUGCCCUACCUGtt (SEQ ID NO. 221) Antisense strand siRNA: CAGGUAGGGCAGGCUCUGCtt (SEQ ID NO. 222)
Target sequence 10: AACTTGCTGTTGCAGGCCAG (SEQ ID NO. 223)
Position in gene sequence: 463 GC content: 57.1% Sense strand siRNA: CUUGCUGUUGCAGGCCAGtt (SEQ ID NO. 224) Antisense strand siRNA: CUGGGCCUGCAACAGCAAGtt (SEQ ID NO. 225)
Target sequence 11: AAGCCCCCGGCTTGGGCCTGG (SEQ ID NO. 226)
Position in gene sequence: 493 GC content: 76.2% Sense strand siRNA: GCCCCCGGCUUGGGCCUGGtt (SEQ ID NO. 227) Antisense strand siRNA: CCAGGCCCAAGCCGGGGGctt (SEQ ID NO. 228)
Target sequence 12: AACTTGCCCCACATTGGCGGT (SEQ ID NO. 229)
Position in gene sequence: 618 GC content: 57.1% Sense strand siRNA: CUUGCCCCACAUUGGCGGUtt (SEQ ID NO. 230) Antisense strand siRNA: ACCGCCAAUGUGGGGCAAGtt (SEQ ID NO. 231)
Target sequence 13: AAGAGCGTTACTCTTGGACCA (SEQ ID NO. 232)
Position in gene sequence: 689 GC content: 47.6% Sense strand siRNA: GAGCGUUACUCUUGGACCAtt (SEQ ID NO. 233) Antisense strand siRNA: UGGUCCAAGAGUAACGCUCtt (SEQ ID NO. 234)
Target sequence 14: AATGTTTCCTTTGACCGAGCT (SEQ ID NO. 235)

Position in gene sequence: 808 GC content: 42.9% Sense strand siRNA: UGUUUCCUUUGACCGAGCUtt (SEQ ID NO. 236) Antisense strand siRNA: AGCUCGGUCAAGGAAACAtt (SEQ ID NO. 237)
Target sequence 15: AAGCAGCTTCCAGCGCAGTCT (SEQ ID NO. 238)
Position in gene sequence: 912 GC content: 57.1% Sense strand siRNA: GCAGCUUCCAGCGCAGUCUtt (SEQ ID NO. 239) Antisense strand siRNA: AGACUGCGCUGGAAGCUGCtt (SEQ ID NO. 240)
Target sequence 16: AAGCAGGGCAAACACAAGGTC (SEQ ID NO. 241)
Position in gene sequence: 946 GC content: 52.4% Sense strand siRNA: GCAGGGCAAACACAAGGUctt (SEQ ID NO. 242) Antisense strand siRNA: GACCUUGUGUUUGCCCUGCtt (SEQ ID NO. 243)
Target sequence 17: AAACACAAGGTCCAGCCCCC (SEQ ID NO. 244)
Position in gene sequence: 955 GC content: 61.9% Sense strand siRNA: ACACAAGGUCCAGCCCCCctt (SEQ ID NO. 245) Antisense strand siRNA: GGGGGGCGUGGACCUUGUGUtt (SEQ ID NO. 246)
Target sequence 18: AAGGTCCAGCCCCCACAAG (SEQ ID NO. 247)
Position in gene sequence: 961 GC content: 61.9% Sense strand siRNA: GGUCCAGCCCCCACAAGtt (SEQ ID NO. 248) Antisense strand siRNA: CUUUGUGGGGGGCGUGGACctt (SEQ ID NO. 249)
Target sequence 19: AAAGCAAGGCCAGAAGTCCCA (SEQ ID NO. 250)
Position in gene sequence: 978 GC content: 52.4% Sense strand siRNA: AGCAAGGCCAGAAGUCCCAtt (SEQ ID NO. 251) Antisense strand siRNA: UGGGACUUCUGGCCUUGCUtt (SEQ ID NO. 252)
Target sequence 20: AAGGCCAGAAGTCCCAGAGGA (SEQ ID NO. 253)
Position in gene sequence: 983 GC content: 57.1% Sense strand siRNA: GGCCAGAAGUCCCAGAGGAtt (SEQ ID NO. 254) Antisense strand siRNA: UCCUCUGGGACUUCUGGCctt (SEQ ID NO. 255)
Target sequence 21: AAGTCCCAGAGGAAAGCCAGA (SEQ ID NO. 256)

Position in gene sequence: 991 GC content: 52.4% Sense strand siRNA: GUCCCAGAGGAAAGCCAGAtt (SEQ ID NO. 257) Antisense strand siRNA: UCUGGCUUCCUCUGGGACTt (SEQ ID NO. 258)
Target sequence 22: AAAGCCAGAAGAGGCCAGCG (SEQ ID NO. 259)
Position in gene sequence: 1003 GC content: 61.9% Sense strand siRNA: AGCCAGAAGAGGCCAGCGt (SEQ ID NO. 260) Antisense strand siRNA: CGCUGGGCCUCUUCUGGCUt (SEQ ID NO. 261)
Target sequence 23: AAGAGGCCAGCGATCTCATC (SEQ ID NO. 262)
Position in gene sequence: 1011 GC content: 57.1% Sense strand siRNA: GAGGCCAGCGAUCUCAUct (SEQ ID NO. 263) Antisense strand siRNA: GAUGAGAUCGCUGGGCCUct (SEQ ID NO. 264)
Target sequence 24: AACAGTCTGGCAGAGGTGCAC (SEQ ID NO. 265)
Position in gene sequence: 1060 GC content: 57.1% Sense strand siRNA: CAGUCUGGCAGAGGUGCAct (SEQ ID NO. 266) Antisense strand siRNA: GUGCACCUCUGCCAGACUGt (SEQ ID NO. 267)
Target sequence 25: AAGGAGCCTCGAGAACTGTTT (SEQ ID NO. 268)
Position in gene sequence: 1111 GC content: 47.6% Sense strand siRNA: GGAGCCUCGAGAACUGUUUtt (SEQ ID NO. 269) Antisense strand siRNA: AAACAGUUCUCGAGGCUCct (SEQ ID NO. 270)
Target sequence 26: AACTGTTTGTGAAGGGCACCA (SEQ ID NO. 271)
Position in gene sequence: 1124 GC content: 47.6% Sense strand siRNA: CUGUUUGUGAAGGGCACCAtt (SEQ ID NO. 272) Antisense strand siRNA: UGGUGCCCUUCACAAACAGt (SEQ ID NO. 273)
Target sequence 27: AAGGGCACCATGAAGGACATT (SEQ ID NO. 274)
Position in gene sequence: 1135 GC content: 47.6% Sense strand siRNA: GGGCACCAUGAAGGACAUUtt (SEQ ID NO. 275) Antisense strand siRNA: AAUGUCCUUCAUGGUGCCct (SEQ ID NO. 276)
Target sequence 28: AAGGACATTCGTGAGAACTTC (SEQ ID NO. 277)

Position in gene sequence: 1147 GC content: 42.9% Sense strand siRNA: GGACAUUCGUGAGAACUUCtt (SEQ ID NO. 278) Antisense strand siRNA: GAAGUUCUCACGAAUGUCctt (SEQ ID NO. 279)
Target sequence 29: AACTTCCAGGACCTGATGCAG (SEQ ID NO. 280)
Position in gene sequence: 1162 GC content: 52.4% Sense strand siRNA: CUUCCAGGACCUGAUGCAGtt (SEQ ID NO. 281) Antisense strand siRNA: CUGCAUCAGGUCCUGGAAGtt (SEQ ID NO. 282)
Target sequence 30: AACCAGAACTGGGAGCGTTAC (SEQ ID NO. 283)
Position in gene sequence: 1312 GC content: 52.4% Sense strand siRNA: CCAGAACUGGGAGCGUUACTt (SEQ ID NO. 284) Antisense strand siRNA: GUAACGCUCCCAGUUCUGGtt (SEQ ID NO. 285)
Target sequence 31: AACTGGGAGCGTTACCTGGCA (SEQ ID NO. 286)
Position in gene sequence: 1318 GC content: 57.1% Sense strand siRNA: CUGGGAGCGUUACCUGGCAtt (SEQ ID NO. 287) Antisense strand siRNA: UGCCAGGUAACGCUCCCAGtt(SEQ ID NO. (SEQ ID NO. 288)
Target sequence 32: AAGAAGTCGTTGATGGATCTG (SEQ ID NO. 289)
Position in gene sequence: 1378 GC content: 42.9% Sense strand siRNA: GAAGUCGUUGAUGGAUCUGtt (SEQ ID NO. 290) Antisense strand siRNA: CAGAUCCAUCAACGACUUCtt (SEQ ID NO. 291)
Target sequence 33: AAGTCGTTGATGGATCTGGCC (SEQ ID NO. 292)
Position in gene sequence: 1381 GC content: 52.4% Sense strand siRNA: GUCGUUGAUGGAUCUGGCCtt (SEQ ID NO. 293) Antisense strand siRNA: GGCCAGAUCCAUCAACGACTt (SEQ ID NO. 294)
Target sequence 34: AATGATGCCTGCCAGCTGCTC (SEQ ID NO.295)
Position in gene sequence: 1402 GC content: 57.1% Sense strand siRNA: UGAUGCCUGCCAGCUGCUCtt (SEQ ID NO. 296) Antisense strand siRNA: GAGCAGCUGGCAGGCAUCAtt (SEQ ID NO. 297)
Target sequence 35: AAAGAAGACCCCTGGCTCTGG (SEQ ID NO. 298)

Position in gene sequence: 1438 GC content: 57.1% Sense strand siRNA: AGAAGACCCCUGGCUCUGGtt (SEQ ID NO. 299) Antisense strand siRNA: CCAGAGCCAGGGGUCUUCUtt (SEQ ID NO. 300) Target sequence 36: AAGACCCCTGGCTCTGGGACC (SEQ ID NO. 301)
Position in gene sequence: 1442 GC content: 66.7% Sense strand siRNA: GACCCCUGGCUCUGGGACtt (SEQ ID NO. 302) Antisense strand siRNA: GGUCCCAGAGCCAGGGGUtt (SEQ ID NO. 303) Target sequence 37: AAGAATTTAAGCAGAAGAAAG (SEQ ID NO. 304)
Position in gene sequence: 1478 GC content: 28.6% Sense strand siRNA: GAAUUUAAGCAGAAGAAAGtt (SEQ ID NO. 305) Antisense strand siRNA: CUUUCUUCUGCUUAAAUUCtt (SEQ ID NO. 306) Target sequence 38: AATTTAAGCAGAAGAAAGCTA (SEQ ID NO. 307)
Position in gene sequence: 1481 GC content: 28.6% Sense strand siRNA: UUUAAGCAGAAGAAAGCUAtt (SEQ ID NO. 308) Antisense strand siRNA: UAGCUUUCUUCUGCUUAAAtt (SEQ ID NO. 309) Target sequence 39: AAGCAGAAGAAAGCTAAGAAG (SEQ ID NO. 310)
Position in gene sequence: 1486 GC content: 38.1% Sense strand siRNA: GCAGAAGAAAGCUAAGAAGtt (SEQ ID NO. 311) Antisense strand siRNA: CUUCUUAGCUUUCUUCUGCtt (SEQ ID NO. 312) Target sequence 40: AAGAAAGCTAAGAAGGTGAAG (SEQ ID NO. 313)
Position in gene sequence: 1492 GC content: 38.1% Sense strand siRNA: GAAAGCUAAGAAGGUGAAGtt (SEQ ID NO. 314) Antisense strand siRNA: CUUCACCUUCUUCUAGCUUUCtt (SEQ ID NO. 315) Target sequence 41: AAAGCTAAGAAGGTGAAGAAG (SEQ ID NO. 316)
Position in gene sequence: 1495 GC content: 38.1% Sense strand siRNA: AGCUAAGAAGGUGAAGAAGtt (SEQ ID NO. 317) Antisense strand siRNA: CUUCUUCACCUUCUUCUAGCUtt (SEQ ID NO. 318) Target sequence 42: AAGAAGGTGAAGAAGGAACCA (SEQ ID NO. 319)

Position in gene sequence: 1501 GC content: 42.9% Sense strand siRNA: GAAGGUGAAGAAGGAACCAtt (SEQ ID NO. 320) Antisense strand siRNA: UGGUCCUUCUUCACCUUCTt (SEQ ID NO. 321)
Target sequence 43: AAGGTGAAGAAGGAACCAGCC (SEQ ID NO. 322)
Position in gene sequence: 1504 GC content: 52.4% Sense strand siRNA: GGUGAAGAAGGAACCAGCCtt (SEQ ID NO. 323) Antisense strand siRNA: GGCUGGUUCCUUCUUCACCTt (SEQ ID NO. 324)
Target sequence 44: AAGAAGGAACCAGCCACAGCC (SEQ ID NO. 325)
Position in gene sequence: 1510 GC content: 57.1% Sense strand siRNA: GAAGGAACCAGCCACAGCCtt (SEQ ID NO. 326) Antisense strand siRNA: GGCUGUGGCUGGUUCCUUCTt (SEQ ID NO. 327)
Target sequence 45: AAGGAACCAGCCACAGCCAGC (SEQ ID NO. 328)
Position in gene sequence: 1513 GC content: 61.9% Sense strand siRNA: GGAACCAGCCACAGCCAGCtt (SEQ ID NO. 329) Antisense strand siRNA: GCUGGCUGUGGCUGGUUCCtt (SEQ ID NO. 330)
Target sequence 46: AACCAGCCACAGCCAGCAAGT (SEQ ID NO. 331)
Position in gene sequence: 1517 GC content: 57.1% Sense strand siRNA: CCAGCCACAGCCAGCAAGUtt (SEQ ID NO. 332) Antisense strand siRNA: ACUUGCUGGCUGUGGCUGGtt (SEQ ID NO. 333)
Target sequence 47: AAGTTGCCCATCGAGGGGGCT (SEQ ID NO. 334)
Position in gene sequence: 1534 GC content: 61.9% Sense strand siRNA: GUUGCCCAUCGAGGGGGGCUtt (SEQ ID NO. 335) Antisense strand siRNA: AGCCCCCUCGAUGGGGCACTt (SEQ ID NO. 336)
Target sequence 48: AAGACCTCGGCCCTGCAGTG (SEQ ID NO. 337)
Position in gene sequence: 1583 GC content: 66.7% Sense strand siRNA: GACCUCGGCCCCUGCAGUGtt (SEQ ID NO. 338) Antisense strand siRNA: CACUGCAGGGGCGGAGGUCTt (SEQ ID NO. 339)
Target sequence 49: AACAAGATGTCATGGCCCGCG (SEQ ID NO. 340)

Position in gene sequence: 1619 GC content: 57.1% Sense strand siRNA: CAAGAUGUCAUGGCCCGCGt (SEQ ID NO. 341) Antisense strand siRNA: CGCGGGCCAUGACAUCUUGt (SEQ ID NO. 342)
Target sequence 50: AAGATGTCATGGCCCGCGCCT (SEQ ID NO. 343)
Position in gene sequence: 1622 GC content: 61.9% Sense strand siRNA: GAUGUCAUGGCCCGCGCCUtt (SEQ ID NO. 344) Antisense strand siRNA: AGGCGCGGGCCAUGACAUCtt (SEQ ID NO. 345)
Target sequence 51: AAGCTGAAGGGGACCACAGAG (SEQ ID NO. 346)
Position in gene sequence: 1651 GC content: 57.1% Sense strand siRNA: GCUGAAGGGGACCACAGAGt (SEQ ID NO. 347) Antisense strand siRNA: CUCUGUGGUCCCCUUCAGCtt (SEQ ID NO. 348)
Target sequence 52: AAGGGGACCACAGAGCTCCTG (SEQ ID NO. 349)
Position in gene sequence: 1657 GC content: 61.9% Sense strand siRNA: GGGGACCACAGAGCUCCUGt (SEQ ID NO. 350) Antisense strand siRNA: CAGGAGCUCUGUGGUCCCCtt (SEQ ID NO. 351)
Target sequence 53: AAGCGGCCCCAGCACCTTCCT (SEQ ID NO. 352)
Position in gene sequence: 1681 GC content: 66.7% Sense strand siRNA: GCGGCCCCAGCACCUUCCUtt (SEQ ID NO. 353) Antisense strand siRNA: AGGAAGGUGCUGGGGGCCGt (SEQ ID NO. 354)
Target sequence 54: AAGCTCTGCCCCCGGCTAGAC (SEQ ID NO. 355)
Position in gene sequence: 1723 GC content: 66.7% Sense strand siRNA: GCUCUGCCCCCGGCUAGAct (SEQ ID NO. 356) Antisense strand siRNA: GUCUAGCCGGGGGCAGAGCtt (SEQ ID NO. 357)
Target sequence 55: AAATCATGGCACTTACCTGG (SEQ ID NO. 358)
Position in gene sequence: 1801 GC content: 47.6% Sense strand siRNA: ACUCAUGGCACUUACCUGGt (SEQ ID NO. 359) Antisense strand siRNA: CCAGGUAAGUGCCAUGAGUtt (SEQ ID NO. 360)
Target sequence 56: AACCTGGCCAAGCTGCCGACA (SEQ ID NO. 361)

Position in gene sequence: 1888 GC content: 61.9% Sense strand siRNA: CCUGGCCAAGCUGCCGACAtt (SEQ ID NO. 362) Antisense strand siRNA: UGUCGGCAGCUUGGCCAGGtt (SEQ ID NO. 363)
Target sequence 57: AAGCTGCCGACAGGTACCACC (SEQ ID NO. 364)
Position in gene sequence: 1897 GC content: 61.9% Sense strand siRNA: GCUGCCGACAGGUACCACtt (SEQ ID NO. 365) Antisense strand siRNA: GGUGGUACCUGUCGGCAGCtt (SEQ ID NO. 366)
Target sequence 58: AAGCACTGTCTCGAACAGGGG (SEQ ID NO. 367)
Position in gene sequence: 1972 GC content: 57.1% Sense strand siRNA: GCACUGUCUCGAACAGGGGtt (SEQ ID NO. 368) Antisense strand siRNA: CCCUGUUCGAGACAGUGCtt (SEQ ID NO. 369)
Target sequence 59: AACAGGGGAAGCAGCAGCTGA (SEQ ID NO. 370)
Position in gene sequence: 1985 GC content: 57.1% Sense strand siRNA: CAGGGGAAGCAGCAGCUGAtt (SEQ ID NO. 371) Antisense strand siRNA: UCAGCUGCUGCUUCCCCUGtt (SEQ ID NO. 372)
Target sequence 60: AAGCAGCAGCTGATGCCCCAG (SEQ ID NO. 373)
Position in gene sequence: 1993 GC content: 61.9% Sense strand siRNA: GCAGCAGCUGAUGCCCCAGtt (SEQ ID NO. 374) Antisense strand siRNA: CUGGGGCAUCAGCUGCUGCtt (SEQ ID NO. 375)
Target sequence 61: AATAGTGCCATATGGCAAACG (SEQ ID NO. 376)
Position in gene sequence: 2050 GC content: 42.9% Sense strand siRNA: UAGUGCCAUAUGGCAAACGtt (SEQ ID NO. 377) Antisense strand siRNA: CGUUUGCCAUAUGGCACUAtt (SEQ ID NO. 378)
Target sequence 62: AAACGGTAGAAGAACTGGATT (SEQ ID NO. 379)
Position in gene sequence: 2066 GC content: 38.1% Sense strand siRNA: ACGGUAGAAGAACUGGAUUt (SEQ ID NO. 380) Antisense strand siRNA: AAUCCAGUUCUUCUACCGUt (SEQ ID NO. 381)
Target sequence 63: AAGAACTGGATTACTTAGAAG (SEQ ID NO. 382)

Position in gene sequence: 2075 GC content: 33.3% Sense strand siRNA: GAACUGGAUUACUUAGAAGtt (SEQ ID NO. 383) Antisense strand siRNA: CUUCUAAGUAAUCCAGUUCtt (SEQ ID NO. 384)
Target sequence 64: AACTGGATTACTTAGAAGTGG (SEQ ID NO. 385)
Position in gene sequence: 2078 GC content: 38.1% Sense strand siRNA: CUGGAUUACUUAGAAGUGGtt (SEQ ID NO. 386) Antisense strand siRNA: CCACUUCUAAGUAAUCCAGtt (SEQ ID NO. 387)
Target sequence 65: AAGTGGAGGCTGAGGCCAAGA (SEQ ID NO. 388)
Position in gene sequence: 2093 GC content: 57.1% Sense strand siRNA: GUGGAGGCUGAGGCCAAGAtt (SEQ ID NO. 389) Antisense strand siRNA: UCUUGGCCUCAGCCUCCACTt (SEQ ID NO. 390)
Target sequence 66: AAGATGGAGAACTTGCGAGCT (SEQ ID NO. 391)
Position in gene sequence: 2110 GC content: 47.6% Sense strand siRNA: GAUGGAGAACUUGCGAGCUtt (SEQ ID NO. 392) Antisense strand siRNA: AGCUCGCAAGUUCUCCAUCtt (SEQ ID NO. 393)
Target sequence 67: AACTTGCGAGCTGCAGTGCCA (SEQ ID NO. 394)
Position in gene sequence: 2119 GC content: 57.1% Sense strand siRNA: CUUGCGAGCUGCAGUGCCAAtt (SEQ ID NO. 395) Antisense strand siRNA: UGGCACUGCAGCUCGCAAGtt (SEQ ID NO. 396)
Target sequence 68: AACCCCTAGCTCTGACTGCCC (SEQ ID NO. 397)
Position in gene sequence: 2144 GC content: 61.9% Sense strand siRNA: CCCCUAGCUCUGACUGCCctt (SEQ ID NO. 398) Antisense strand siRNA: GGGCAGUCAGAGCUAGGGGtt (SEQ ID NO. 399)
Target sequence 69: AAGGACACCCAGCCCAGCTAT (SEQ ID NO. 400)
Position in gene sequence: 2176 GC content: 57.1% Sense strand siRNA: GGACACCCAGCCCAGCUAUtt (SEQ ID NO. 401) Antisense strand siRNA: AUAGCUGGGCUGGGUGUCctt (SEQ ID NO. 402)
Target sequence 70: AATGGACCTTACAACGACGTG (SEQ ID NO. 403)

Position in gene sequence: 2206 GC content: 47.6% Sense strand siRNA: UGGACCUUACAACGACGUGtt (SEQ ID NO. 404) Antisense strand siRNA: CACGUCGUUGUAAGGUCCAtt (SEQ ID NO. 405)
Target sequence 71: AACGACGTGGACATCCCTGGC (SEQ ID NO. 406)
Position in gene sequence: 2218 GC content: 61.9% Sense strand siRNA: CGACGUGGACAUCCCUGGctt (SEQ ID NO. 407) Antisense strand siRNA: GCCAGGGAUGUCCACGUCGtt (SEQ ID NO. 408)
Target sequence 72: AAGCTGCCTCACAAGGATGGT (SEQ ID NO. 409)
Position in gene sequence: 2251 GC content: 52.4% Sense strand siRNA: GCUGCCUCACAAGGAUGGUtt (SEQ ID NO. 410) Antisense strand siRNA: ACCAUCCUUGUGAGGCAGctt (SEQ ID NO. 411)
Target sequence 73: AAGGATGGTAATAGCTGTAAT (SEQ ID NO. 412)
Position in gene sequence: 2263 GC content: 33.3% Sense strand siRNA: GGAUGGUAAUAGCUGUAAUtt (SEQ ID NO. 413) Antisense strand siRNA: AUUACAGCUAUUACCAUCCtt (SEQ ID NO. 414)
Target sequence 74: AATAGCTGTAATGTGGGAAGC (SEQ ID NO. 415)
Position in gene sequence: 2272 GC content: 42.9% Sense strand siRNA: UAGCUGUAAUGUGGGAAGCtt (SEQ ID NO. 416) Antisense strand siRNA: GCUUCCCACAUAUACAGCUAtt (SEQ ID NO. 417)
Target sequence 75: AATGTGGGAAGCCCCTTTGCC (SEQ ID NO. 418)
Position in gene sequence: 2281 GC content: 57.1% Sense strand siRNA: UGUGGGAAGCCCCUUGCCtt (SEQ ID NO. 419) Antisense strand siRNA: GGCAAAGGGGCUUCCCAAtt (SEQ ID NO. 420)
Target sequence 76: AAGCCCCTTTGCCAAGGACTT (SEQ ID NO. 421)
Position in gene sequence: 2289 GC content: 52.4% Sense strand siRNA: GCCCCUUGCCAAGGACUUt (SEQ ID NO. 422) Antisense strand siRNA: AAGUCCUUGGCAAAGGGGctt (SEQ ID NO. 423)
Target sequence 77: AAGGACTTCCTGCCCAAGATG (SEQ ID NO. 424)

Position in gene sequence: 2302 GC content: 52.4% Sense strand siRNA: GGACUUCCUGCCCAAGAUGtt (SEQ ID NO. 425) Antisense strand siRNA: CAUCUUGGGCAGGAAGUCctt (SEQ ID NO. 426)
Target sequence 78: AAGATGGAGGATGGCACCCCTG (SEQ ID NO. 427)
Position in gene sequence: 2317 GC content: 57.1% Sense strand siRNA: GAUGGAGGAUGGCACCCUGtt (SEQ ID NO. 428) Antisense strand siRNA: CAGGGUGCCAUCCUCCAUCtt (SEQ ID NO. 429)
Target sequence 79: AAATCAACAAAATGATTTCTT (SEQ ID NO. 430)
Position in gene sequence: 2378 GC content: 19% Sense strand siRNA: AUCAACAAAAUGAUUUCUUt (SEQ ID NO. 431) Antisense strand siRNA: AAGAAUCAUUUUGUUGAUtt (SEQ ID NO. 432)
Target sequence 80: AACAAAATGATTTCTTTCTGG (SEQ ID NO. 433)
Position in gene sequence: 2383 GC content: 28.6% Sense strand siRNA: CAAAUGAUUUCUUCUGGtt (SEQ ID NO. 434) Antisense strand siRNA: CCAGAAAGAAUCAUUUGtt (SEQ ID NO. 435)
Target sequence 81: AAAATGATTTCTTTCTGGAGG (SEQ ID NO. 436)
Position in gene sequence: 2386 GC content: 33.3% Sense strand siRNA: AAUGAUUUCUUCUGGAGGtt (SEQ ID NO. 437) Antisense strand siRNA: CCUCCAGAAAGAAUCAUUt (SEQ ID NO. 438)
Target sequence 82: AATGATTTCTTTCTGGAGGAA (SEQ ID NO. 439)
Position in gene sequence: 2388 GC content: 33.3% Sense strand siRNA: UGAUUUCUUCUGGAGGAAtt (SEQ ID NO. 440) Antisense strand siRNA: UUCCUCCAGAAAGAAUCAtt (SEQ ID NO. 441)
Target sequence 83: AACGCCCATAAACGTATCAGC (SEQ ID NO. 442)
Position in gene sequence: 2407 GC content: 47.6% Sense strand siRNA: CGCCCAUAAACGUAUCAGctt (SEQ ID NO. 443) Antisense strand siRNA: GCUGAUACGUUUAUGGGCGtt (SEQ ID NO. 444)
Target sequence 84: AAACGTATCAGCTCCCAGATG (SEQ ID NO. 445)

Position in gene sequence: 2416 GC content: 47.6% Sense strand siRNA: ACGUAUCAGCUCCCAGAUGtt (SEQ ID NO. 446) Antisense strand siRNA: CAUCUGGGAGCUGAUACGUtt (SEQ ID NO. 447)
Target sequence 85: AAGGCCTCTATGGGGCCATCC (SEQ ID NO. 448)
Position in gene sequence: 2501 GC content: 61.9% Sense strand siRNA: GGCCUCUAUGGGGGCCAUCctt (SEQ ID NO. 449) Antisense strand siRNA: GGAUGGCCCCAUAGAGGCCctt (SEQ ID NO. 450)
Target sequence 86: AAGTGGTGACTGCCGGCACCA (SEQ ID NO. 451)
Position in gene sequence: 2528 GC content: 61.9% Sense strand siRNA: GUGGUGACUGCCGGCACCAtt (SEQ ID NO. 452) Antisense strand siRNA: UGGUGCCGGCAGUCACCActt (SEQ ID NO. 453)
Target sequence 87: AATGCCCGGCCTGACCGAGTA (SEQ ID NO. 454)
Position in gene sequence: 2590 GC content: 61.9% Sense strand siRNA: UGCCCCGGCCUGACCGAGUAtt (SEQ ID NO. 455) Antisense strand siRNA: UACUCGGUCAGGCCGGGCAtt (SEQ ID NO. 456)
Target sequence 88: AAAGCCATGGTGCAGGCCCCA (SEQ ID NO. 457)
Position in gene sequence: 2623 GC content: 61.9% Sense strand siRNA: AGCCAUGGUGCAGGCCCCCAtt (SEQ ID NO. 458) Antisense strand siRNA: UGGGGCCUGCACCAUGGCUtt (SEQ ID NO. 459)
Target sequence 89: AAGAGCTGTGGATTGCAGCTG (SEQ ID NO. 460)
Position in gene sequence: 2681 GC content: 52.4% Sense strand siRNA: GAGCUGUGGAUUGCAGCUGtt (SEQ ID NO. 461) Antisense strand siRNA: CAGCUGCAAUCCACAGCUctt (SEQ ID NO. 462)
Target sequence 90: AAGAGCAGGGGGCACTGATCTA (SEQ ID NO. 463)
Position in gene sequence: 2773 GC content: 52.4% Sense strand siRNA: GAGCAGGGGGCACUGAUCUAtt (SEQ ID NO. 464) Antisense strand siRNA: UAGAUCAGUGCCCCUGCUctt (SEQ ID NO. 465)
Target sequence 91: AAGACAGCCACTACTGTGGGC (SEQ ID NO. 466)

Position in gene sequence: 2800 GC content: 57.1% Sense strand siRNA: GACAGCCACUACUGUGGGCtt (SEQ ID NO. 467) Antisense strand siRNA: GCCCACAGUAGUGGCUGUCtt (SEQ ID NO. 468)
Target sequence 92: AAAATCTTCAACTACGGCCGC (SEQ ID NO. 469)
Position in gene sequence: 2839 GC content: 47.6% Sense strand siRNA: AAUCUUCAACUACGGCCGctt (SEQ ID NO. 470) Antisense strand siRNA: GCGGCCGUAGUUGAAGAUUtt (SEQ ID NO. 471)
Target sequence 93: AATCTTCAACTACGGCCGCAT (SEQ ID NO. 472)
Position in gene sequence: 2841 GC content: 47.6% Sense strand siRNA: UCUUCAACUACGGCCGCAUtt (SEQ ID NO. 473) Antisense strand siRNA: AUGCGGCCGUAGUUGAAGAtt (SEQ ID NO. 474)
Target sequence 94: AACTACGGCCGCATCTATGGT (SEQ ID NO. 475)
Position in gene sequence: 2848 GC content: 52.4% Sense strand siRNA: CUACGGCCGCAUCUAUGGUtt (SEQ ID NO. 476) Antisense strand siRNA: ACCAUAGAUGCGGCCGUAGtt (SEQ ID NO. 477)
Target sequence 95: AATGCAGTTTAACCACCGGCT (SEQ ID NO. 478)
Position in gene sequence: 2898 GC content: 47.6% Sense strand siRNA: UGCAGUUUAACCACCGGCUtt (SEQ ID NO. 479) Antisense strand siRNA: AGCCGGUGGUUAAACUGCAtt (SEQ ID NO. 480)
Target sequence 96: AACCACCGGCTCACACAGCAG (SEQ ID NO. 481)
Position in gene sequence: 2908 GC content: 61.9% Sense strand siRNA: CCACCGGCUCACACAGCAGtt (SEQ ID NO. 482) Antisense strand siRNA: CUGCUGUGUGAGCCGGUGGtt (SEQ ID NO. 483)
Target sequence 97: AAGGCCCAGCAGATGTACGCT (SEQ ID NO. 484)
Position in gene sequence: 2941 GC content: 57.1% Sense strand siRNA: GGCCCAGCAGAUGUACGCUtt (SEQ ID NO. 485) Antisense strand siRNA: AGCGUACAUCUGCUGGGGCtt (SEQ ID NO. 486)
Target sequence 98: AAGGGCCTCCGCTGGTATCGG (SEQ ID NO. 487)

Position in gene sequence: 2968 GC content: 66.7% Sense strand siRNA: GGGCCUCCGCUGGUAUCGGtt (SEQ ID NO. 488) Antisense strand siRNA: CCGAUACCAGCGGAGGCCctt (SEQ ID NO. 489)
Target sequence 99: AACCTCCCAGTGGACAGGACT (SEQ ID NO. 490)
Position in gene sequence: 3025 GC content: 57.1% Sense strand siRNA: CCUCCCAGUGGACAGGACUtt (SEQ ID NO. 491) Antisense strand siRNA: AGUCCUGUCCACUGGGAGGtt (SEQ ID NO. 492)
Target sequence 100: AAGGTCCAGAGAGAACTGCA (SEQ ID NO. 493)
Position in gene sequence: 3079 GC content: 47.6% Sense strand siRNA: GGUCCAGAGAGAAACUGCAtt (SEQ ID NO. 494) Antisense strand siRNA: UGCAGUUUCUCUCUGGACctt (SEQ ID NO. 495)
Target sequence 101: AAAGTCAAGGAAGTCACAGT (SEQ ID NO. 496)
Position in gene sequence: 3092 GC content: 42.9% Sense strand siRNA: ACUGCAAGGAAGUCACAGUtt (SEQ ID NO. 497) Antisense strand siRNA: ACUGUGACUCCUUGCAGUtt (SEQ ID NO. 498)
Target sequence 102: AAGGAAGTCACAGTGGAAGAA (SEQ ID NO. 499)
Position in gene sequence: 3099 GC content: 42.9% Sense strand siRNA: GGAAGUCACAGUGGAAGAAtt (SEQ ID NO. 500) Antisense strand siRNA: UUCUCCACUGUGACUUCctt (SEQ ID NO. 501)
Target sequence 103: AAGTCACAGTGGAAGAAGTGG (SEQ ID NO. 502)
Position in gene sequence: 3103 GC content: 47.6% Sense strand siRNA: GUCACAGUGGAAGAAGUGGtt (SEQ ID NO. 503) Antisense strand siRNA: CCACUUCUCCACUGUGACtt (SEQ ID NO. 504)
Target sequence 104: AAGAAGTGGGAGGTGGTTGCT (SEQ ID NO. 505)
Position in gene sequence: 3115 GC content: 52.4% Sense strand siRNA: GAAGUGGGAGGUGGUUGCUtt (SEQ ID NO. 506) Antisense strand siRNA: AGCAACCACCUCCCACUUCtt (SEQ ID NO. 507)
Target sequence 105: AAGTGGGAGGTGGTTGCTGAA (SEQ ID NO. 508)

Position in gene sequence: 3118 GC content: 52.4% Sense strand siRNA: GUGGGAGGUGGUUGCUGAA _{tt} (SEQ ID NO. 509) Antisense strand siRNA: UUCAGCAACCACCUCCCAC _{tt} (SEQ ID NO. 510)
Target sequence 106: AACGGGCATGGAAGGGGGGCA (SEQ ID NO. 511)
Position in gene sequence: 3137 GC content: 66.7% Sense strand siRNA: CGGGCAUGGAAGGGGGGGCA _{tt} (SEQ ID NO. 512) Antisense strand siRNA: UGCCCCCUUCCAUGCCCG _{tt} (SEQ ID NO. 513)
Target sequence 107: AAGGGGGGCACAGAGTCAGAA (SEQ ID NO. 514)
Position in gene sequence: 3148 GC content: 57.1% Sense strand siRNA: GGGGGGCACAGAGUCAGAA _{tt} (SEQ ID NO. 515) Antisense strand siRNA: UUCUGACUCUGUGCCCCC _{tt} (SEQ ID NO. 516)
Target sequence 108: AAATGTTCAATAAGCTTGAGA (SEQ ID NO. 517)
Position in gene sequence: 3167 GC content: 28.6% Sense strand siRNA: AUGUUCAAUAAGCUUGAGA _{tt} (SEQ ID NO. 518) Antisense strand siRNA: UCUCAAGCUUAUUGAACAU _{tt} (SEQ ID NO. 519)
Target sequence 109: AATAAGCTTGAGAGCATTGCT (SEQ ID NO. 520)
Position in gene sequence: 3175 GC content: 38.1% Sense strand siRNA: UAAGCUUGAGAGCAUUGCU _{tt} (SEQ ID NO. 521) Antisense strand siRNA: AGCAAUGCUCUCAAGCUUA _{tt} (SEQ ID NO. 522)
Target sequence 110: AAGCTTGAGAGCATTGCTACG (SEQ ID NO. 523)
Position in gene sequence: 3178 GC content: 47.6% Sense strand siRNA: GCUUGAGAGCAUUGCUACG _{tt} (SEQ ID NO. 524) Antisense strand siRNA: CGUAGCAAUGCUCUCAAGC _{tt} (SEQ ID NO. 525)
Target sequence 111: AAGAGTTTATGACCAGCCGTG (SEQ ID NO. 526)
Position in gene sequence: 3269 GC content: 47.6% Sense strand siRNA: GAGUUUAUGACCAGCCGUG _{tt} (SEQ ID NO. 527) Antisense strand siRNA: CACGGCUGGUCAUAAACUC _{tt} (SEQ ID NO. 528)
Target sequence 112: AATTGGGTGGTACAGAGCTCT (SEQ ID NO. 529)

Position in gene sequence: 3292 GC content: 47.6% Sense strand siRNA: UUGGGUGGUACAGAGCUCUtt (SEQ ID NO. 530) Antisense strand siRNA: AGAGCUCUGUACCACCCAAtt (SEQ ID NO. 531)
Target sequence 113: AAGTGGCTGTTTGAAGAGTTT (SEQ ID NO. 532)
Position in gene sequence: 3349 GC content: 38.1% Sense strand siRNA: GUGGCUGUUUGAAGAGUUUtt (SEQ ID NO. 533) Antisense strand siRNA: AAACUCUCAAACAGCCACtt (SEQ ID NO. 534)
Target sequence 114: AAGAGTTTGCCATAGATGGGC (SEQ ID NO. 535)
Position in gene sequence: 3362 GC content: 47.6% Sense strand siRNA: GAGUUUGCCAUAGAUGGGCtt (SEQ ID NO. 536) Antisense strand siRNA: GCCCAUCUAUGGCAAACUCtt (SEQ ID NO. 537)
Target sequence 115: AACCTCTTGACCAGGTGCATG (SEQ ID NO. 538)
Position in gene sequence: 3469 GC content: 52.4% Sense strand siRNA: CCUCUUGACCAGGUGCAUGtt (SEQ ID NO. 539) Antisense strand siRNA: CAUGCACCUGGUCAAGAGGtt (SEQ ID NO. 540)
Target sequence 116: AAGCTGGGTCTGAATGACTTG (SEQ ID NO. 541)
Position in gene sequence: 3499 GC content: 47.6% Sense strand siRNA: GCUGGGUCUGAAUGACUUGtt (SEQ ID NO. 542) Antisense strand siRNA: CAAGUCAUUCAGACCCAGCtt (SEQ ID NO. 543)
Target sequence 117: AATGACTTGCCCCAGTCAGTC (SEQ ID NO. 544)
Position in gene sequence: 3511 GC content: 52.4% Sense strand siRNA: UGACUUGCCCCAGUCAGUCtt (SEQ ID NO. 545) Antisense strand siRNA: GACUGACUGGGGCAAGUCAtt (SEQ ID NO. 546)
Target sequence 118: AAGGAAGTGACCATGGATTGT (SEQ ID NO. 547)
Position in gene sequence: 3571 GC content: 42.9% Sense strand siRNA: GGAAGUGACCAUGGAUUGUtt (SEQ ID NO. 548) Antisense strand siRNA: ACAAUCCAUGGUCACUUCtt (SEQ ID NO. 549)
Target sequence 119: AAGTGACCATGGATTGTAAAA (SEQ ID NO. 550)

Position in gene sequence: 3575 GC content: 33.3% Sense strand siRNA: GUGACCAUGGAUUGUAAAAtt (SEQ ID NO. 551) Antisense strand siRNA: UUUUACAAUCCAUGGUCACtt (SEQ ID NO. 552)
Target sequence 120: AAAACCCCTTCCAACCCAACt (SEQ ID NO. 553)
Position in gene sequence: 3592 GC content: 47.6% Sense strand siRNA: AACCCCUUCCAACCCAACUtt (SEQ ID NO. 554) Antisense strand siRNA: AGUUGGGUUGGAAGGGGUUtt (SEQ ID NO. 555)
Target sequence 121: AACCCCTTCCAACCCAACtGG (SEQ ID NO. 556)
Position in gene sequence: 3594 GC content: 57.1% Sense strand siRNA: CCCCUUCCAACCCAACUGGtt (SEQ ID NO. 557) Antisense strand siRNA: CCAGUUGGGUUGGAAGGGGtt (SEQ ID NO. 558)
Target sequence 122: AACCCAACtGGGATGGAAAGG (SEQ ID NO. 559)
Position in gene sequence: 3604 GC content: 52.4% Sense strand siRNA: CCCAACUGGGGAUGGAAAGGtt (SEQ ID NO. 560) Antisense strand siRNA: CCUUUCCAUCCCAGUUGGGtt (SEQ ID NO. 561)
Target sequence 123: AACTGGGATGGAAAGGAGATA (SEQ ID NO. 562)
Position in gene sequence: 3609 GC content: 42.9% Sense strand siRNA: CUGGGAUGGAAAGGAGAUAtt (SEQ ID NO. 563) Antisense strand siRNA: UAUCUCCUUUCCAUCCCAGtt (SEQ ID NO. 564)
Target sequence 124: AAAGGAGATACGGGATTCCCC (SEQ ID NO. 565)
Position in gene sequence: 3620 GC content: 52.4% Sense strand siRNA: AGGAGAUACGGGAUUCCCCtt (SEQ ID NO. 566) Antisense strand siRNA: GGGGAAUCCCGUAUCUCCUtt (SEQ ID NO. 567)
Target sequence 125: AAGCGCTGGATATTACCAGA (SEQ ID NO. 568)
Position in gene sequence: 3647 GC content: 42.9% Sense strand siRNA: GCGCUGGAUAUUUACCAGAtt (SEQ ID NO. 569) Antisense strand siRNA: UCUGGUAAAUAUCCAGCGCtt (SEQ ID NO. 570)
Target sequence 126: AATTGAACTCACCAAAGGCTC (SEQ ID NO. 571)

Position in gene sequence: 3669 GC content: 42.9% Sense strand siRNA: UUGAACUCACCAAAGGCUCtt (SEQ ID NO. 572) Antisense strand siRNA: GAGCCUUUGGUGAGUUCAtt (SEQ ID NO. 573)
Target sequence 127: AACTCACCAAAGGCTCCTTGG (SEQ ID NO. 574)
Position in gene sequence: 3674 GC content: 52.4% Sense strand siRNA: CUCACCAAAGGCUCCUUGGtt (SEQ ID NO. 575) Antisense strand siRNA: CCAAGGAGCCUUUGGUGAGtt (SEQ ID NO. 576)
Target sequence 128: AAAGGCTCCTTGGAACGA (SEQ ID NO. 577)
Position in gene sequence: 3682 GC content: 42.9% Sense strand siRNA: AGGCUCCUUGGAAAAACGAtt (SEQ ID NO. 578) Antisense strand siRNA: UCGUUUUCCAAGGAGCCUtt (SEQ ID NO. 579)
Target sequence 129: AAAACGAAGCCAGCCTGGAC (SEQ ID NO. 580)
Position in gene sequence: 3695 GC content: 52.4% Sense strand siRNA: AACGAAGCCAGCCUGGACtt (SEQ ID NO. 581) Antisense strand siRNA: GUCCAGGCUGGCUUCGUUtt (SEQ ID NO. 571)
Target sequence 130: AACGAAGCCAGCCTGGACCA (SEQ ID NO. 572)
Position in gene sequence: 3697 GC content: 57.1% Sense strand siRNA: ACGAAGCCAGCCUGGACCAtt (SEQ ID NO. 573) Antisense strand siRNA: UGGUCCAGGCUGGCUUCGUtt (SEQ ID NO. 574)

What is claimed is:

1. A polynucleotide encoding a recombinant polypeptide comprising an organelle localization signal and a protein transduction domain.
- 5 2. The polynucleotide of claim 1, wherein the organelle localization signal is operably linked to the protein transduction domain.
3. The polynucleotide of claim 1, wherein the recombinant polypeptide
10 comprises a cleavage site for removing the protein transduction domain.
4. The polynucleotide of claim 1, wherein the protein transduction domain is positioned within the recombinant polypeptide to be cleaved within a targeted organelle.
- 15 5. The polynucleotide of claim 1, wherein the recombinant polypeptide comprises a viral polypeptide.
6. The polynucleotide of claim 5, wherein the viral polypeptide
20 comprises a viral surface polypeptide.
7. The polynucleotide of claim 6, wherein the viral surface polypeptide comprises a bacteriophage surface polypeptide.
- 25 8. The polynucleotide of claim 7, wherein the bacteriophage surface polypeptide comprises bacteriophage lambda surface polypeptide .
9. The polynucleotide of claim 7, wherein the viral surface polypeptide is selected from the group consisting of capsid and tail proteins.
- 30 10. The polynucleotide of claim 6, wherein the viral surface peptide comprises between 80-100% homology to gpD (SEQ. ID NO. 5).

11. The polynucleotide of claim 1, wherein the organelle localization signal comprises a mitochondrial localization signal.

12. The polynucleotide of claim 11, wherein the mitochondrial
5 localization signal comprises a sequence having 80-100% homology to a
mitochondrial localization signal selected from the group consisting of hexokinase
I, amine oxidase (flavin-containing) A, hexokinase IV, pancreatic beta cell form,
peripheral benzodiazepine receptor-related protein, metaxin 2, putative
mitochondrial outer membrane protein import receptor (hTOM), glutathione
10 transferase; voltage-dependent anion channel 2 (outer mitochondrial membrane
protein porin), hexokinase IV, cytochrome b5, peripheral benzodiazepine receptor,
germ cell kinase anchor S-AKAP84, A kinase anchor protein, carnitine O-
palmitoyltransferase I precursor, hexokinase II, amine oxidase (flavin-containing)
B, long-chain-fatty-acid--CoA ligase 2, long-chain-fatty-acid--CoA ligase 1
15 (palmitoyl-CoA ligase), voltage-dependent anion channel 1, metaxin 1, Human
putative outer mitochondrial membrane 34 kDa translocase hTOM34, voltage-
dependent anion channel 4 (outer mitochondrial membrane protein porin),
cytochrome-b5 reductase, voltage-dependent anion channel 3 (outer
mitochondrial membrane protein porin), Mitochondrial import receptor subunit
20 TOM20 homolog (Mitochondrial 20 kd outer membrane protein) (Outer
mitochondrial membrane receptor TOM20), tumorous imaginal discs homolog
precursor (HTID-1), and SEQ. ID Nos. 7-177.

13. The polynucleotide of claim 1, wherein the protein transduction
25 domain comprises a plurality of amino acid residues having a net positive charge
under physiological conditions.

14. The polynucleotide of claim 1, wherein the protein transduction
domain comprises 8-15 amino acid residues.

30

15. The polynucleotide of claim 1, wherein the protein transduction
domain comprises 11 arginine residues.

16. The polynucleotide of claim 1, wherein the protein transduction domain RKKRRQRRR (SEQ. ID. NO. 4).

17. A recombinant polypeptide comprising an organelle localization
5 signal and a protein transduction domain.

18. The recombinant polypeptide of claim 17, wherein the organelle localization signal is operably linked to the protein transduction domain.

19. The recombinant polypeptide of claim 17, wherein the recombinant
10 polypeptide comprises a cleavage site for removing the protein transduction domain.

20. The recombinant polypeptide of claim 17, wherein the protein
15 transduction domain is positioned within the recombinant polypeptide to be cleaved within a targeted organelle.

21. The recombinant polypeptide of claim 17, wherein the recombinant
polypeptide is operably linked to a vector.

20

22. The recombinant polypeptide of claim 17, wherein the vector
comprises a viral vector.

23. The recombinant polypeptide of claim 22, wherein the viral vector
25 comprises a bacteriophage vector.

24. The recombinant polypeptide of claim 23, wherein the bacteriophage
vector comprises a lambda bacteriophage vector.

25. The recombinant polypeptide of claim 17, wherein the recombinant
30 polypeptide is located on a surface of the vector.

26. The recombinant polypeptide of claim 17, wherein the protein transduction domain enables the recombinant polypeptide to cross a cell membrane.

5 27. The recombinant polypeptide of claim 17, wherein the organelle localization signal directs the recombinant polypeptide to a specific organelle.

28. A polynucleotide encoding a recombinant polypeptide, wherein the recombinant polypeptide comprises a chloroplast localization signal and a protein
10 transduction domain.

29. The polynucleotide of claim 28, wherein the organelle localization signal is operably linked to the protein transduction domain.

15 30. The polynucleotide of claim 28, wherein the recombinant polypeptide comprises a cleavage site for removing the protein transduction domain.

31. The polynucleotide of claim 28, wherein the protein transduction domain is positioned within the recombinant polypeptide to be cleaved within a
20 targeted organelle.

32. The polynucleotide of claim 28, wherein the recombinant polypeptide comprises a viral polypeptide.

25 33. The polynucleotide of claim 32, wherein the viral polypeptide comprises a viral surface polypeptide.

34. The polynucleotide of claim 33, wherein the viral surface polypeptide comprises a bacteriophage surface polypeptide.
30

35. The polynucleotide of claim 34, wherein the bacteriophage surface polypeptide comprises a bacteriophage lambda surface polypeptide.

36. The polynucleotide of claim 28, wherein the chloroplast localization signal has 80-100% homology to a chloroplast localization signal selected from the group consisting of transit peptide domain of the apicoblast ribosomal protein S9, Pea glutathione reductase (GR) signal peptide, NH2-terminus of Cr-RSH
5 encoding a putative guanosine 3',5'-bispyrophosphate (ppGpp) synthase-degradase, 14-3-3 proteins, chloroplast signal recognition particle including cpSRP54, cpSRP43 subunits or a fragment thereof, chloroplast transit peptides AtOEP7 including transmembrane domain (TMD) and its C-terminal neighboring seven-amino acid region, THI1 N-terminal chloroplastic transit peptide, and SEQ.
10 ID Nos. 178-194.

37. The polynucleotide of claim 33, wherein the viral surface polypeptide comprises a polypeptide having 80-100% homology to gpD (SEQ. ID NO. 5)

15 38. The polynucleotide of claim 28, wherein the protein transduction domain comprises a plurality of amino acid residues having a net positive charge under physiological conditions.

39. The polynucleotide of claim 28, wherein the protein transduction
20 domain comprises 8-15 amino acid residues.

40. The polynucleotide of claim 28, wherein the protein transduction domain comprises 11 arginine residues.

25 41. A recombinant viral vector comprising the polynucleotide of claim 1.

42. The recombinant viral vector of claim 41, wherein the vector comprises a bacteriophage vector.

30 43. The recombinant viral vector of claim 42, wherein the vector comprises a lambda bacteriophage vector.

44. A cell comprising a modified organelle, wherein said modified organelle comprises a bacteriophage.

45. The cell of claim 44, wherein the organelle is selected from the group consisting of a mitochondrion and a chloroplast.

5 46. The cell of claim 44, wherein the cell comprises a eukaryotic cell.

47. The cell of claim 44, wherein the bacteriophage comprises lambda bacteriophage.

10 48. The cell of claim 44, where the bacteriophage is a recombinant bacteriophage.

15 49. The cell of claim 44, wherein the bacteriophage comprises a polynucleotide encoding a mitochondrial localization signal and a protein transduction domain.

50. The cell of claim 44, wherein the bacteriophage comprises a polynucleotide encoding a chloroplast localization signal and a protein transduction domain.

20

51. The cell of claim 44, wherein the chloroplast localization signal has 80-100% homology to a chloroplast localization signal selected from the group consisting of transit peptide domain of the apicoplast ribosomal protein S9, Pea glutathione reductase (GR) signal peptide, NH2-terminus of Cr-RSH encoding a putative guanosine 3',5'-bispyrophosphate (ppGpp) synthase-degradase, 14-3-3 proteins, chloroplast signal recognition particle including cpSRP54, cpSRP43 subunits or a fragment thereof, chloroplast transit peptides AtOEP7 including transmembrane domain (TMD) and its C-terminal neighboring seven-amino acid region, THI1 N-terminal chloroplastic transit peptide, and SEQ. ID Nos. 178-194.

30

52. The cell of claim 49, wherein the protein transduction domain comprises a plurality of amino acid residues having a net positive charge under physiological conditions.

53. The cell of claim 49, wherein the protein transduction domain comprises 8-15 amino acid residues.

54. The cell of claim 49, wherein the protein transduction domain
5 comprises 11 arginine residues.

55. A method of transfecting a cell, said method comprising the step of:
contacting the cell with a vector operably linked to a polypeptide, the
polypeptide comprising a protein transduction domain and an organelle targeting
10 signal.

56. The method of claim 55, wherein the vector expresses the
polypeptide on a surface of the vector.

15 57. The method of claim 56, wherein the vector traverses the cell's outer
membrane via the protein transduction domain.

58. The method of claim 57, wherein said organelle targeting signal
directs the vector to a specific organelle.
20

59. The method of claim 58, wherein the vector traverses a membrane
of the specific organelle.

60. The method of claim 55, wherein the organelle targeting signal is
25 specific for mitochondria or chloroplasts.

61. The method of claim 55, wherein the vector comprises a viral vector.

62. The method of claim 61, wherein the viral vector comprises a
30 bacteriophage vector.

63. The method of claim 62, wherein the bacteriophage vector
comprises a lambda bacteriophage vector.

64. The method of claim 55, wherein the organelle targeting signal has 80-100% homology to an organelle targeting signal selected from the group consisting of hexokinase I, amine oxidase (flavin-containing) A, hexokinase IV, pancreatic beta cell form, peripheral benzodiazepine receptor-related protein, metaxin 2, putative mitochondrial outer membrane protein import receptor (hTOM), glutathione transferase; voltage-dependent anion channel 2 (outer mitochondrial membrane protein porin), hexokinase IV, cytochrome b5, peripheral benzodiazepine receptor, germ cell kinase anchor S-AKAP84, A kinase anchor protein, carnitine O-palmitoyltransferase I precursor, hexokinase II, amine oxidase (flavin-containing) B, long-chain-fatty-acid--CoA ligase 2, long-chain-fatty-acid--CoA ligase 1 (palmitoyl-CoA ligase), voltage-dependent anion channel 1, metaxin 1, Human putative outer mitochondrial membrane 34 kDa translocase hTOM34, voltage-dependent anion channel 4 (outer mitochondrial membrane protein porin), cytochrome-b5 reductase, voltage-dependent anion channel 3 (outer mitochondrial membrane protein porin), Mitochondrial import receptor subunit TOM20 homolog (Mitochondrial 20 kd outer membrane protein) (Outer mitochondrial membrane receptor TOM20), tumorous imaginal discs homolog precursor (HTID-1), transit peptide domain of the apicoblast ribosomal protein S9, Pea glutathione reductase (GR) signal peptide, NH2-terminus of Cr-RSH encoding a putative guanosine 3',5'-bispyrophosphate (ppGpp) synthase-degradase, 14-3-3 proteins, chloroplast signal recognition particle including cpSRP54, cpSRP43 subunits or a fragment thereof, chloroplast transit peptides AtOEP7 including transmembrane domain (TMD) and its C-terminal neighboring seven-amino acid region, TH11 N-terminal chloroplastic transit peptide, and SEQ. ID NOs. 7-194.

65. The method of claim 55, wherein the protein transduction domain comprises a plurality of amino acid residues having a net positive charge under physiological conditions.

30

66. The method of claim 55, wherein the protein transduction domain comprises 8-15 amino acid residues.

67. The method of claim 55, wherein the protein transduction domain comprises 11 arginine residues.

5 66. A method of modifying an organelle, the method comprising the step of

transfecting the cell with a recombinant lambdaphage, the recombinant lambdaphage comprising a polynucleotide encoding an organelle localization signal operably linked to a bacteriophage lambda surface protein;

10 wherein the organelle localization signal is displayed on a surface of the recombinant lambdaphage and directs the recombinant lambdaphage to the organelle; and

wherein the recombinant lambdaphage introduces a polynucleotide into the organelle.

15 67. The method of claim 66, wherein the organelle is a mitochondrion, and the organelle localization signal comprises at least a fragment of subunit VIII of human cytochrome oxidase.

20 68. A kit for transfecting organelles, the kit comprising:
a polynucleotide encoding an organelle localization signal operably linked to a bacteriophage lambda surface polypeptide; and
bacteriophage lambda packaging components for preparing a recombinant lambda vector.

25 69. The kit of claim 68, wherein the localization signal comprises a chloroplast localization signal.

30 70. The kit of claim 68, wherein the localization signal comprises a mitochondrial localization signal.

71. The kit of claim 68, wherein the localization signal comprises at least a fragment of subunit VIII of human cytochrome oxidase.

72. A system for transfecting organelles, said system comprising

a polynucleotide encoding an organelle localization signal peptide operably linked to a bacteriophage surface polypeptide; and
a recombinant bacteriophage vector.

5 73. A method for transfecting organelles, the method comprising the step of

introducing a recombinant viral vector into the cytosol of a cell, wherein the recombinant viral vector displays an organelle localization signal on a surface of the vector for directing the vector to an organelle to be transfected.

10

74. The method of claim 73, wherein the recombinant viral vector is lambda bacteriophage and said organelle localization signal has 80-100% homology to an organelle localization signal selected from the group consisting of hexokinase I, amine oxidase (flavin-containing) A, hexokinase IV, pancreatic beta
15 cell form, peripheral benzodiazepine receptor-related protein, metaxin 2, putative mitochondrial outer membrane protein import receptor (hTOM), glutathione transferase; voltage-dependent anion channel 2 (outer mitochondrial membrane protein porin), hexokinase IV, cytochrome b5, peripheral benzodiazepine receptor, germ cell kinase anchor S-AKAP84, A kinase anchor protein, carnitine O-
20 palmitoyltransferase I precursor, hexokinase II, amine oxidase (flavin-containing) B, long-chain-fatty-acid-CoA ligase 2, long-chain-fatty-acid-CoA ligase 1 (palmitoyl-CoA ligase), voltage-dependent anion channel 1, metaxin 1, Human putative outer mitochondrial membrane 34 kDa translocase hTOM34, voltage-
25 dependent anion channel 4 (outer mitochondrial membrane protein porin), cytochrome-b5 reductase, voltage-dependent anion channel 3 (outer mitochondrial membrane protein porin), Mitochondrial import receptor subunit TOM20 homolog (Mitochondrial 20 kd outer membrane protein) (Outer mitochondrial membrane receptor TOM20), tumorous imaginal discs homolog precursor (HTID-1), transit peptide domain of the apicoblast ribosomal protein S9,
30 Pea glutathione reductase (GR) signal peptide, NH2-terminus of Cr-RSH encoding a putative guanosine 3',5'-bispyrophosphate (ppGpp) synthase-degradase, 14-3-3 proteins, chloroplast signal recognition particle including cpSRP54, cpSRP43 subunits or a fragment thereof, chloroplast transit peptides AtOEP7 including transmembrane domain (TMD) and its C-terminal neighboring

seven-amino acid region, TH11 N-terminal chloroplastic transit peptide, and SEQ. ID Nos. 7-194.

75. A composition comprising a recombinant polypeptide comprising an
5 organelle localization signal operably linked to a protein transduction domain,
wherein the recombinant polypeptide is operably linked to a polynucleotide.

76. A method for modifying the metabolism of a cell, the method
comprising:
10 contacting the cell with a recombinant vector displaying a
recombinant polypeptide comprising a mitochondrial localization signal operably
linked to a protein transduction domain, the recombinant vector comprising a
polynucleotide encoding a functional respiratory chain component, wherein the
functional respiratory chain component compensates for the at least one defective
15 respiratory chain component when expressed by the cell.

77. The method of claim 76, wherein the functional respiratory chain
component is expressed in at least one mitochondrion of the cell.

20 78. The method of claim 76, wherein the vector encodes the
recombinant polypeptide displayed on the surface of the vector.

79. The method of claim 78, wherein the vector traverses the cell's outer
membrane via the protein transduction domain.
25

80. The method of claim 76, wherein the cell is a eukaryotic cell.

81. A method for modifying cytochrome oxidase activity in a cell, the
method comprising:
30 contacting the cell with a recombinant vector displaying a
recombinant polypeptide comprising a mitochondrial localization signal operably
linked to a protein transduction domain, the recombinant vector encoding a
functional cytochrome oxidase subunit, wherein the functional cytochrome oxidase
subunit modifies cytochrome oxidase activity of the cell.

82. The method of claim 81, wherein the functional cytochrome oxidase subunit is expressed in at least one mitochondrion of the cell.

5 83. The method of claim 81, wherein the vector encodes the recombinant polypeptide displayed on a surface of the vector.

84. The method of claim 81, wherein the vector traverses the cell's outer membrane via the protein transduction domain.

10

85. A method for compensating for a mtDNA mutation in a host, the method comprising the steps of:

contacting a host's cell having a mtDNA mutation with a recombinant vector expressing a recombinant polypeptide comprising a mitochondrial localization
15 signal operably linked to a protein transduction domain, the recombinant vector also encoding a functional product corresponding to the mtDNA mutation.

86. The method of claim 84, wherein the contacting occurs in vivo or in vitro.

20

87. The method of claim 84, wherein the vector expresses the recombinant polypeptide on a surface of the vector.

88. The method of claim 84, wherein the vector traverses the cell's outer
25 membrane via the protein transduction domain.

89. A recombinant bacteriophage comprising a modified surface polypeptide, wherein the modified surface polypeptide comprises a protein transduction domain.

30

90. A recombinant bacteriophage comprising a modified surface polypeptide, wherein the modified surface polypeptide comprises an organelle localization signal.

91. A recombinant bacteriophage comprising a modified surface polypeptide, wherein the modified surface polypeptide comprises a protein transduction domain operably linked to an organelle localization signal.

5 92. A method of treating a mitochondrial disease in a host comprising:
 contacting a host's cell with a recombinant vector displaying a recombinant polypeptide comprising a mitochondrial localization signal operably linked to a protein transduction domain, the recombinant vector encoding a functional mitochondrial polypeptide, wherein the recombinant vector transfects at least one
10 of the host's mitochondria enabling the host's cell to express the functional mitochondrial polypeptide in the at least one transfected mitochondrion.

 93. The method of claim 84, wherein the contacting occurs in vivo or in vitro.

15

 94. The method of claim 91, wherein the mitochondrial disease is selected from the group consisting of Alpers Disease; Barth syndrome; β -oxidation defects; carnitine-acyl-carnitine deficiency; carnitine deficiency; co-enzyme Q10 deficiency; Complex I deficiency; Complex II deficiency; Complex III
20 deficiency; Complex IV deficiency; Complex V deficiency; cytochrome c oxidase (COX) deficiency; Chronic Progressive External Ophthalmoplegia Syndrome (CPEO); CPT I Deficiency; CPT II deficiency; Glutaric Aciduria Type II; lactic acidosis; Long-Chain Acyl-CoA Dehydrogenase Deficiency (LCAD); LCHAD; mitochondrial cytopathy; mitochondrial DNA depletion; mitochondrial
25 encephalopathy; mitochondrial myopathy; Mitochondrial Encephalomyopathy with Lactic Acidosis and Strokelike episodes (MELAS); Myoclonus Epilepsy with Ragged Red Fibers (MERRF); Maternally Inherited Leigh's Syndrome (MILS); Myogastrointestinal encephalomyopathy (MNGIE); Neuropathy, ataxia and retinitis pigmentosa (NARP); Leber's Hereditary Optic Neuropathy (LHON); Progressive
30 external ophthalmoplegia (PEO); Pearson syndrome; Kearns-Sayre syndrome (KSS); Leigh's syndrome; intermittent dysautonomia; pyruvate carboxylase deficiency; pyruvate dehydrogenase deficiency; respiratory chain mutations and deletions; Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD); SCHAD; and Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD).

95. A method for producing a mtDNA depleted cell comprising:
contacting the cell with at least one siRNA directed to POL γ .
- 5 96. The method of claim 95, wherein the siRNA is selected from the
siRNAs listed in TABLE 3 or a sequence having 80-100% homology to the siRNAs
listed in TABLE 3 or SEQ ID NOs. 195-574.
- 10 97. The method of claim 95, wherein a target sequence of POL γ RNA
inhibition is selected from the POL γ target sequences in TABLE 3.
98. A method of depleting mtDNA in a cell comprising:
contacting the cell with an inhibitor of mtDNA replication or transcription.
- 15 99. The method of claim 98, wherein the inhibitor of mtDNA replication is
an antisense polynucleotide or a small inhibitory RNA.
100. The method of claim 98, wherein the inhibitor comprises DNA, RNA
or a combination thereof.
- 20 101. The method of claim 98, wherein the inhibitor is selected from Table
3.
102. The method of claim 98, wherein the inhibitor is specific for a gene
25 involved in mitochondrial DNA transcription or replication.
103. The method of claim 102, wherein the gene is selected from the
group consisting of POL γ , TFAM A and B, and mtSSB.
- 30 104. The method of claim 102, wherein the gene encodes a mitochondrial
polymerase.

105. A cell comprising an inhibitory polynucleotide that specifically binds to a polynucleotide encoding a mitochondrial polymerase.

5

106. A cell comprising an siRNA specific for a mitochondrial polymerase.

107. The cell of claim 106, wherein the mitochondrial polymerase comprises Poly.

10

108. The cell of claim 106, wherein the siRNA is selected from the siRNAs listed in Table 3.

109. The cell of claim 105, wherein the inhibitory polynucleotide comprises an antisense polynucleotide.

15

110. The cell of claim 105, wherein the cell comprises a vector that expresses the inhibitory polynucleotide.

20

111 A cell comprising an inhibitory polynucleotide that specifically binds to a mitochondrial polymerase and inhibits the mitochondrial polymerase.

25

112. A virus particle comprising:

(a) a protein transduction domain operably linked to a surface of the virus particle;

25

(b) a targeting signal operably linked to a surface of the virus particle; and


(c) a polynucleotide.

30

113. A vector comprising:

a polynucleotide encoding a protein transduction domain operably linked to a targeting signal, wherein the protein transduction domain operably linked to the targeting signal is expressed on an exterior surface of the vector.

Figure 1A






Figure 1B




Figure 1C




Figure 2A






Figure 2B



Full Length mtDNA/GFP Ligated into
18656

Figure 3

Figure 4



BEST AVAILABLE COPY




Figure 5A

Figure 5B

Figure 6A






Figure 6B



BEST AVAILABLE CCPY

Figure 7



BEST AVAILABLE CCPY

SEQUENCE LISTING

Incorporated by reference in its entirety from the accompanying compact disk.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.